



## Clinical trial results:

### An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443

#### Summary

EudraCT number	2015-001870-16
Trial protocol	DE GB SE ES FR BE IT
Global end of trial date	21 August 2023

#### Results information

Result version number	v2 (current)
This version publication date	30 November 2024
First version publication date	08 March 2024
Version creation reason	<ul style="list-style-type: none"><li>• Correction of full data set</li></ul> Updates to the endpoints section after resolving CTg results.

#### Trial information

##### Trial identification

Sponsor protocol code	ISIS 396443-CS11
-----------------------	------------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02594124
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Biogen
Sponsor organisation address	250 Binney Street, Cambridge, Massachusetts, United States, 02142
Public contact	Study Medical Director, Biogen, clinicaltrials@biogen.com
Scientific contact	Study Medical Director, Biogen, clinicaltrials@biogen.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-001448-PIP01-13
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	21 August 2023
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	21 August 2023
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of the trial is to evaluate the long-term safety and tolerability of nusinersen (ISIS 396443) administered by intrathecal (IT) injection to participants with spinal muscular atrophy (SMA) who previously participated in investigational studies of ISIS 396443.

Protection of trial subjects:

Written informed consent was obtained from each subject's parent or legal guardian prior to evaluations being performed for eligibility. Adequate time to review the information in the informed consent and ask questions concerning all portions of the conduct of the study was provided. Through the informed consent process, awareness of the purpose of the study, the procedures, the benefits and risks of the study, the discomforts and the precautions taken was made. Any side effects or other health issues occurring during the study were followed up by the study doctor. Subjects were able to stop taking part in the study at any time without giving any reason.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	04 November 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 177
Country: Number of subjects enrolled	Italy: 25
Country: Number of subjects enrolled	Germany: 23
Country: Number of subjects enrolled	Spain: 15
Country: Number of subjects enrolled	Japan: 11
Country: Number of subjects enrolled	Canada: 8
Country: Number of subjects enrolled	France: 7
Country: Number of subjects enrolled	Korea, Republic of: 5
Country: Number of subjects enrolled	Sweden: 5
Country: Number of subjects enrolled	Türkiye: 5
Country: Number of subjects enrolled	Australia: 4
Country: Number of subjects enrolled	United Kingdom: 3
Country: Number of subjects enrolled	Hong Kong: 3
Country: Number of subjects enrolled	Belgium: 1
Worldwide total number of subjects	292
EEA total number of subjects	76

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	89
Children (2-11 years)	187
Adolescents (12-17 years)	12
Adults (18-64 years)	4
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Participants were enrolled at investigative sites in Australia, Belgium, Canada, Germany, Spain, France, United Kingdom, Hong Kong, Italy, Japan, Republic of Korea, Sweden, Turkey, and the United States from 04 November 2015 to 21 August 2023.

### Pre-assignment

Screening details:

A total of 292 participants with infantile and later onset spinal muscular atrophy (SMA) who previously participated in ISIS 396443-CS3B[NCT02193074], ISIS 396443-CS4[NCT02292537], ISIS 396443-CS3A[NCT01839656], ISIS 396443-CS12[NCT02052791] and 232SM202[NCT02462759] were enrolled and treated in Modified Maintenance Dosing Regimen (MMDR) period.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Infantile SMA Onset CS3A

Arm description:

Participants who received nusinersen in study ISIS 396443-CS3A, in an open-label period, received maintenance doses of nusinersen, intrathecal (IT) injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.

Arm type	Experimental
Investigational medicinal product name	Nusinersen
Investigational medicinal product code	
Other name	ISIS 396443
Pharmaceutical forms	Solution for injection
Routes of administration	Intrathecal use

Dosage and administration details:

Administered as specified in the treatment arm.

<b>Arm title</b>	Infantile SMA Onset CS3B Previous Control
------------------	---

Arm description:

Participants who received sham procedures in study ISIS 396443-CS3B, in a double-blind period, received 4 loading doses of nusinersen IT injection on Days 1, 15, 29, and 64 followed by maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.

Arm type	Experimental
Investigational medicinal product name	Nusinersen
Investigational medicinal product code	
Other name	ISIS 396443
Pharmaceutical forms	Solution for injection
Routes of administration	Intrathecal use

Dosage and administration details:

Administered as specified in the treatment arm.

<b>Arm title</b>	Infantile SMA Onset CS3B Previous ISIS 396443
------------------	---

Arm description:

Participants who received nusinersen in study ISIS 396443-CS3B, in the double-blind period, received 3 sham procedures on Days 1, 15, and 64 and 1 loading dose of nusinersen IT injection on Day 29 followed by maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720,

840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.

Arm type	Experimental
Investigational medicinal product name	Nusinersen
Investigational medicinal product code	
Other name	ISIS 396443
Pharmaceutical forms	Solution for injection
Routes of administration	Intrathecal use

Dosage and administration details:

Administered as specified in the treatment arm.

<b>Arm title</b>	Infantile SMA Onset 232SM202
------------------	------------------------------

Arm description:

Participants who received nusinersen in study 232SM202 (i.e., Part 2) in an open-label period, received maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.

Arm type	Experimental
Investigational medicinal product name	Nusinersen
Investigational medicinal product code	
Other name	ISIS 396443
Pharmaceutical forms	Solution for injection
Routes of administration	Intrathecal use

Dosage and administration details:

Administered as specified in the treatment arm.

<b>Arm title</b>	Later SMA Onset CS12 Type 2
------------------	-----------------------------

Arm description:

Participants who received nusinersen in study ISIS 396443-CS12 in an open-label period, received maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.

Arm type	Experimental
Investigational medicinal product name	Nusinersen
Investigational medicinal product code	
Other name	ISIS 396443
Pharmaceutical forms	Solution for injection
Routes of administration	Intrathecal use

Dosage and administration details:

Administered as specified in the treatment arm.

<b>Arm title</b>	Later SMA Onset CS12 Type 3
------------------	-----------------------------

Arm description:

Participants who received nusinersen in study ISIS 396443-CS12 in an open-label period, received maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.

Arm type	Experimental
Investigational medicinal product name	Nusinersen
Investigational medicinal product code	
Other name	ISIS 396443
Pharmaceutical forms	Solution for injection
Routes of administration	Intrathecal use

Dosage and administration details:

Administered as specified in the treatment arm.

<b>Arm title</b>	Later SMA Onset CS4 Previous Control
------------------	--------------------------------------

Arm description:

Participants who received sham procedures in the study ISIS 396443-CS4 in a double-blind period received 3 loading doses of nusinersen administered by IT injection on Days 1, 29, and 85 followed by maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960,

1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.

Arm type	Experimental
Investigational medicinal product name	Nusinersen
Investigational medicinal product code	
Other name	ISIS 396443
Pharmaceutical forms	Solution for injection
Routes of administration	Intrathecal use
Dosage and administration details:	
Administered as specified in the treatment arm.	
<b>Arm title</b>	Later SMA Onset CS4 Previous ISIS 396443

Arm description:

Participants who received nusinersen in the study ISIS 396443-CS4 in a double-blind period received 2 loading doses of nusinersen administered by IT injection on Days 1 and 85 and 1 sham procedure on Day 29 followed by maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.

Arm type	Experimental
Investigational medicinal product name	Nusinersen
Investigational medicinal product code	
Other name	ISIS 396443
Pharmaceutical forms	Solution for injection
Routes of administration	Intrathecal use
Dosage and administration details:	
Administered as specified in the treatment arm.	
<b>Arm title</b>	Later SMA Onset 232SM202

Arm description:

Participants who received nusinersen in study 232SM202 (i.e., Part 2) in an open-label period, received maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.

Arm type	Experimental
Investigational medicinal product name	Nusinersen
Investigational medicinal product code	
Other name	ISIS 396443
Pharmaceutical forms	Solution for injection
Routes of administration	Intrathecal use
Dosage and administration details:	
Administered as specified in the treatment arm.	

Number of subjects in period 1	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443
Started	13	24	65
Completed	10	10	42
Not completed	3	14	23
Consent withdrawn by subject	2	3	5
Physician decision	-	2	-
Commercial Drug	-	1	6
Adverse event, non-fatal	-	5	8
Reason Not Specified	1	3	4

<b>Number of subjects in period 1</b>	Infantile SMA Onset 232SM202	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3
Started	12	20	25
Completed	7	12	20
Not completed	5	8	5
Consent withdrawn by subject	1	8	4
Physician decision	-	-	-
Commercial Drug	3	-	-
Adverse event, non-fatal	1	-	-
Reason Not Specified	-	-	1

<b>Number of subjects in period 1</b>	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443	Later SMA Onset 232SM202
Started	42	83	8
Completed	19	44	5
Not completed	23	39	3
Consent withdrawn by subject	13	19	-
Physician decision	-	1	-
Commercial Drug	7	11	2
Adverse event, non-fatal	2	2	-
Reason Not Specified	1	6	1

## Baseline characteristics

### Reporting groups

Reporting group title	Infantile SMA Onset CS3A
Reporting group description: Participants who received nusinersen in study ISIS 396443-CS3A, in an open-label period, received maintenance doses of nusinersen, intrathecal (IT) injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.	
Reporting group title	Infantile SMA Onset CS3B Previous Control
Reporting group description: Participants who received sham procedures in study ISIS 396443-CS3B, in a double-blind period, received 4 loading doses of nusinersen IT injection on Days 1, 15, 29, and 64 followed by maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.	
Reporting group title	Infantile SMA Onset CS3B Previous ISIS 396443
Reporting group description: Participants who received nusinersen in study ISIS 396443-CS3B, in the double-blind period, received 3 sham procedures on Days 1, 15, and 64 and 1 loading dose of nusinersen IT injection on Day 29 followed by maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.	
Reporting group title	Infantile SMA Onset 232SM202
Reporting group description: Participants who received nusinersen in study 232SM202 (i.e., Part 2) in an open-label period, received maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.	
Reporting group title	Later SMA Onset CS12 Type 2
Reporting group description: Participants who received nusinersen in study ISIS 396443-CS12 in an open-label period, received maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.	
Reporting group title	Later SMA Onset CS12 Type 3
Reporting group description: Participants who received nusinersen in study ISIS 396443-CS12 in an open-label period, received maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.	
Reporting group title	Later SMA Onset CS4 Previous Control
Reporting group description: Participants who received sham procedures in the study ISIS 396443-CS4 in a double-blind period received 3 loading doses of nusinersen administered by IT injection on Days 1, 29, and 85 followed by maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.	
Reporting group title	Later SMA Onset CS4 Previous ISIS 396443
Reporting group description: Participants who received nusinersen in the study ISIS 396443-CS4 in a double-blind period received 2 loading doses of nusinersen administered by IT injection on Days 1 and 85 and 1 sham procedure on Day 29 followed by maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.	
Reporting group title	Later SMA Onset 232SM202
Reporting group description: Participants who received nusinersen in study 232SM202 (i.e., Part 2) in an open-label period, received maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.	



Reporting group values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443
Number of subjects	13	24	65
Age categorical Units: Subjects			
Infants and toddlers (28 days - 23 months)	0	24	65
Children (2 - 11 years)	13	0	0
12 - 17 years	0	0	0
Adults (18 - 64 years)	0	0	0
Gender categorical Units: Subjects			
Male	7	9	29
Female	6	15	36
Ethnicity Units: Subjects			
Hispanic or Latino	1	3	10
Not Hispanic or Latino	12	18	47
Not reported	0	3	8
Race Units: Subjects			
American Indian or Alaska native	0	0	1
Asian	1	1	2
Black or African American	0	0	3
White	10	18	47
Multiple	1	2	1
Other	1	0	3
Not reported	0	3	8

Reporting group values	Infantile SMA Onset 232SM202	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3
Number of subjects	12	20	25
Age categorical Units: Subjects			
Infants and toddlers (28 days - 23 months)	0	0	0
Children (2 - 11 years)	12	19	10
12 - 17 years	0	0	12
Adults (18 - 64 years)	0	1	3
Gender categorical Units: Subjects			
Male	6	12	10
Female	6	8	15
Ethnicity Units: Subjects			
Hispanic or Latino	2	2	6
Not Hispanic or Latino	7	18	19
Not reported	3	0	0
Race Units: Subjects			
American Indian or Alaska native	0	0	0
Asian	4	1	1

Black or African American	0	0	1
White	5	18	23
Multiple	0	1	0
Other	0	0	0
Not reported	3	0	0

<b>Reporting group values</b>	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443	Later SMA Onset 232SM202
Number of subjects	42	83	8
Age categorical Units: Subjects			
Infants and toddlers (28 days - 23 months)	0	0	0
Children (2 - 11 years)	42	83	8
12 - 17 years	0	0	0
Adults (18 - 64 years)	0	0	0
Gender categorical Units: Subjects			
Male	21	37	5
Female	21	46	3
Ethnicity Units: Subjects			
Hispanic or Latino	0	4	1
Not Hispanic or Latino	37	69	5
Not reported	5	10	2
Race Units: Subjects			
American Indian or Alaska native	0	0	1
Asian	7	16	0
Black or African American	1	1	0
White	26	53	4
Multiple	3	3	0
Other	0	0	1
Not reported	5	10	2

<b>Reporting group values</b>	Total		
Number of subjects	292		
Age categorical Units: Subjects			
Infants and toddlers (28 days - 23 months)	89		
Children (2 - 11 years)	187		
12 - 17 years	12		
Adults (18 - 64 years)	4		
Gender categorical Units: Subjects			
Male	136		
Female	156		
Ethnicity Units: Subjects			
Hispanic or Latino	29		
Not Hispanic or Latino	232		

Not reported	31		
Race			
Units: Subjects			
American Indian or Alaska native	2		
Asian	33		
Black or African American	6		
White	204		
Multiple	11		
Other	5		
Not reported	31		

## End points

### End points reporting groups

Reporting group title	Infantile SMA Onset CS3A
Reporting group description: Participants who received nusinersen in study ISIS 396443-CS3A, in an open-label period, received maintenance doses of nusinersen, intrathecal (IT) injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.	
Reporting group title	Infantile SMA Onset CS3B Previous Control
Reporting group description: Participants who received sham procedures in study ISIS 396443-CS3B, in a double-blind period, received 4 loading doses of nusinersen IT injection on Days 1, 15, 29, and 64 followed by maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.	
Reporting group title	Infantile SMA Onset CS3B Previous ISIS 396443
Reporting group description: Participants who received nusinersen in study ISIS 396443-CS3B, in the double-blind period, received 3 sham procedures on Days 1, 15, and 64 and 1 loading dose of nusinersen IT injection on Day 29 followed by maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.	
Reporting group title	Infantile SMA Onset 232SM202
Reporting group description: Participants who received nusinersen in study 232SM202 (i.e., Part 2) in an open-label period, received maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.	
Reporting group title	Later SMA Onset CS12 Type 2
Reporting group description: Participants who received nusinersen in study ISIS 396443-CS12 in an open-label period, received maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.	
Reporting group title	Later SMA Onset CS12 Type 3
Reporting group description: Participants who received nusinersen in study ISIS 396443-CS12 in an open-label period, received maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.	
Reporting group title	Later SMA Onset CS4 Previous Control
Reporting group description: Participants who received sham procedures in the study ISIS 396443-CS4 in a double-blind period received 3 loading doses of nusinersen administered by IT injection on Days 1, 29, and 85 followed by maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.	
Reporting group title	Later SMA Onset CS4 Previous ISIS 396443
Reporting group description: Participants who received nusinersen in the study ISIS 396443-CS4 in a double-blind period received 2 loading doses of nusinersen administered by IT injection on Days 1 and 85 and 1 sham procedure on Day 29 followed by maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.	
Reporting group title	Later SMA Onset 232SM202
Reporting group description: Participants who received nusinersen in study 232SM202 (i.e., Part 2) in an open-label period, received maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.	

**Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)**

End point title	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) <sup>[1]</sup>
-----------------	--

End point description:

AE:unfavorable and unintended sign, symptom, or disease temporally associated with study/use of an investigational drug, whether or not it's considered related to investigational drug. SAE:AE that in view of either Investigator/Sponsor, meets any of the following criteria: results in death;is life-threatening;i.e.poses risk of death, hospitalization/it's prolongation;results in a persistent or significant incapacity or substantial disruption of normal life functions;results in congenital anomaly or birth defect in offspring;is an important event in the opinion of Investigator/Sponsor. TEAE:if it was present prior to first dose of nusinersen or first sham procedure in index study and subsequently worsened in severity/was not present prior to first dose of nusinersen or first sham procedure in index study but subsequently appeared. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11.

End point type	Primary
----------------	---------

End point timeframe:

From Day 1 up to the end of the study (up to 2848 days)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13	24	65	12
Units: participants				
AEs	13	24	65	12
SAEs	11	23	59	9

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	25	42	83
Units: participants				
AEs	20	25	42	80
SAEs	12	6	26	47

End point values	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: participants				
AEs	8			
SAEs	5			

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants With Vital Sign Abnormalities Reported as AEs

End point title	Number of Participants With Vital Sign Abnormalities Reported as AEs <sup>[2]</sup>
-----------------	---

End point description:

The vital sign assessments included blood pressure, temperature, pulse rate, and respiratory rate. Participants with abnormalities in these assessments recorded as AEs were reported. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11.

End point type	Primary
----------------	---------

End point timeframe:

From Day 1 up to the end of the study (up to 2848 days)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13	24	65	12
Units: participants				
Bradycardia	1	0	6	1
Tachycardia	2	4	5	1
Pyrexia	13	15	50	5
Body Temperature Increased	0	1	1	0
Heart Rate Increased	3	2	4	3
Oxygen Saturation Decreased	1	9	20	2
Respiratory Rate Increased	0	0	1	0
Tachypnoea	0	0	1	1

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	25	42	83
Units: participants				
Bradycardia	0	0	1	0
Tachycardia	0	0	1	2
Pyrexia	10	3	21	39

Body Temperature Increased	0	0	1	0
Heart Rate Increased	0	0	2	0
Oxygen Saturation Decreased	0	1	2	3
Respiratory Rate Increased	0	0	0	0
Tachypnoea	0	0	1	0

End point values	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: participants				
Bradycardia	0			
Tachycardia	0			
Pyrexia	5			
Body Temperature Increased	0			
Heart Rate Increased	0			
Oxygen Saturation Decreased	0			
Respiratory Rate Increased	0			
Tachypnoea	0			

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants With Weight Abnormalities Reported as AEs

End point title	Number of Participants With Weight Abnormalities Reported as AEs <sup>[3]</sup>
-----------------	---

End point description:

Weight decrease was characterized by a decrease of  $\geq 7\%$  from baseline and weight increase was characterized by an increase of  $\geq 7\%$  from baseline. Participants with these abnormalities recorded as AEs were reported. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11.

End point type	Primary
----------------	---------

End point timeframe:

From Day 1 up to the end of the study (up to 2848 days)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13	24	65	12
Units: participants				
Weight Decreased	0	0	3	1
Weight Increased	0	0	0	0

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	25	42	83
Units: participants				
Weight Decreased	0	1	1	3
Weight Increased	0	0	5	0

End point values	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: participants				
Weight Decreased	0			
Weight Increased	0			

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants With Neurological Abnormalities Reported as AEs

End point title	Number of Participants With Neurological Abnormalities Reported as AEs <sup>[4]</sup>
-----------------	---

End point description:

Participants with abnormalities in neurological examinations recorded as AEs were reported. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11.

End point type	Primary
----------------	---------

End point timeframe:

From Day 1 up to the end of the study (up to 2848 days)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13	24	65	12
Units: participants				
Areflexia	2	0	1	0
Hyporeflexia	1	0	0	0



Nystagmus	0	0	4	1
Motor Dysfunction	0	0	1	0
Muscle Contractions Involuntary	0	0	0	1
Myoclonus	0	0	0	0
Paraesthesia	0	0	0	0
Tremor	1	0	1	0

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	25	42	83
Units: participants				
Areflexia	1	0	1	1
Hyporeflexia	0	0	0	0
Nystagmus	0	0	0	0
Motor Dysfunction	0	0	0	0
Muscle Contractions Involuntary	2	1	1	4
Myoclonus	1	0	0	0
Paraesthesia	0	1	0	1
Tremor	1	1	1	3

End point values	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: participants				
Areflexia	0			
Hyporeflexia	0			
Nystagmus	0			
Motor Dysfunction	0			
Muscle Contractions Involuntary	0			
Myoclonus	0			
Paraesthesia	1			
Tremor	0			

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants With Laboratory Abnormalities Reported as AEs

End point title	Number of Participants With Laboratory Abnormalities Reported as AEs <sup>[5]</sup>
-----------------	---

## End point description:

Laboratory investigations included hematology, coagulation, serum chemistry and urinalysis parameters. Participants with abnormalities in these laboratory investigations recorded as AEs were reported. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11.

End point type	Primary
----------------	---------

## End point timeframe:

From Day 1 up to the end of the study (up to 2848 days)

## Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13	24	65	12
Units: participants				
Anaemia	1	0	6	1
Leukocytosis	1	0	3	0
Leukopenia	0	1	0	0
Lymphopenia	0	0	0	0
Neutropenia	0	0	2	0
Neutrophilia	0	0	2	0
Pancytopenia	0	0	0	0
Thrombocytopenia	0	0	1	1
Thrombocytosis	0	0	0	1
Hypertransaminaemia	0	0	1	0
Pyuria	0	0	0	0
Urinary Tract Infection	3	3	11	1
Alanine Aminotransferase Increased	0	1	3	0
Aspartate Aminotransferase Increased	0	1	2	0
Blood Albumin Decreased	0	0	0	1
Blood Bicarbonate Decreased	0	0	2	0
Blood Calcium Decreased	0	0	1	0
Blood Osmolarity Increased	0	0	0	0
Blood Potassium Abnormal	0	1	0	0
Blood Potassium Decreased	0	0	0	1
Blood Potassium Increased	0	0	1	0
Crystal Urine Present	0	0	0	0
Full Blood Count Decreased	0	0	1	0
Full Blood Count Increased	0	0	1	0
Gamma-Glutamyltransferase Increased	0	2	3	0
Haemoglobin Decreased	0	1	2	1
Hepatic Enzyme Increased	0	0	1	0
Liver Function Test Increased	0	1	1	0
Mean Platelet Volume Decreased	0	0	0	1
Neutrophil Count Decreased	0	0	0	0
Neutrophil Count Increased	0	0	1	0
Platelet Count Decreased	0	0	2	0
Platelet Count Increased	0	0	0	1
Protein Urine Present	0	1	1	0

Red Blood Cell Count Increased	0	0	0	1
Transaminases Increased	0	0	0	0
Urine Ketone Body Present	0	0	0	0
White Blood Cell Count Increased	0	0	4	0
White Blood Cells Urine	0	0	1	0
White Blood Cells Urine Positive	0	0	0	1
Hypercalcaemia	0	0	1	0
Hyperglycaemia	0	0	0	0
Hypernatraemia	0	0	2	0
Hypoalbuminaemia	0	0	1	0
Hypocalcaemia	0	2	0	0
Hypochloraemia	0	0	1	1
Hypoglycaemia	2	0	5	0
Hypokalaemia	1	3	10	0
Hyponatraemia	0	0	1	2
Electrolyte Imbalance	0	0	1	1
Bilirubinuria	0	0	0	0
Haematuria	1	1	0	0
Ketonuria	0	0	0	0
Leukocyturia	0	1	0	0
Proteinuria	0	1	7	1
Bandaemia	0	0	1	0

<b>End point values</b>	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	25	42	83
Units: participants				
Anaemia	2	0	1	1
Leukocytosis	0	0	1	2
Leukopenia	0	0	0	1
Lymphopenia	0	0	0	1
Neutropenia	0	0	0	0
Neutrophilia	0	0	0	2
Pancytopenia	0	0	0	1
Thrombocytopenia	0	0	0	0
Thrombocytosis	0	0	0	0
Hypertransaminasaemia	0	0	0	1
Pyuria	0	1	0	0
Urinary Tract Infection	2	1	4	7
Alanine Aminotransferase Increased	0	0	0	1
Aspartate Aminotransferase Increased	0	0	0	0
Blood Albumin Decreased	0	0	0	0
Blood Bicarbonate Decreased	0	0	0	0
Blood Calcium Decreased	0	0	0	0
Blood Osmolarity Increased	0	0	1	0
Blood Potassium Abnormal	0	0	0	0
Blood Potassium Decreased	0	0	0	0

Blood Potassium Increased	0	0	0	0
Crystal Urine Present	0	0	4	6
Full Blood Count Decreased	0	0	0	0
Full Blood Count Increased	0	0	0	0
Gamma-Glutamyltransferase Increased	0	0	0	0
Haemoglobin Decreased	0	0	0	0
Hepatic Enzyme Increased	0	0	2	0
Liver Function Test Increased	0	0	0	0
Mean Platelet Volume Decreased	0	0	0	0
Neutrophil Count Decreased	0	0	1	0
Neutrophil Count Increased	0	0	0	0
Platelet Count Decreased	0	0	0	0
Platelet Count Increased	0	0	0	0
Protein Urine Present	0	0	1	3
Red Blood Cell Count Increased	0	0	0	0
Transaminases Increased	0	0	1	0
Urine Ketone Body Present	0	0	1	0
White Blood Cell Count Increased	0	0	0	0
White Blood Cells Urine	0	0	0	0
White Blood Cells Urine Positive	0	0	0	1
Hypercalcaemia	0	0	0	0
Hyperglycaemia	0	0	0	2
Hypernatraemia	0	0	1	1
Hypoalbuminaemia	0	0	0	0
Hypocalcaemia	0	0	0	1
Hypochloraemia	0	0	0	0
Hypoglycaemia	0	0	1	2
Hypokalaemia	0	0	1	2
Hyponatraemia	0	0	0	1
Electrolyte Imbalance	0	0	0	1
Bilirubinuria	0	0	0	1
Haematuria	0	1	1	2
Ketonuria	0	0	0	1
Leukocyturia	0	0	0	2
Proteinuria	0	2	2	8
Bandaemia	0	0	0	0

End point values	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: participants				
Anaemia	1			
Leukocytosis	0			
Leukopenia	0			
Lymphopenia	0			
Neutropenia	0			
Neutrophilia	0			
Pancytopenia	0			

Thrombocytopenia	0			
Thrombocytosis	0			
Hypertransaminasaemia	0			
Pyuria	0			
Urinary Tract Infection	1			
Alanine Aminotransferase Increased	0			
Aspartate Aminotransferase Increased	0			
Blood Albumin Decreased	0			
Blood Bicarbonate Decreased	0			
Blood Calcium Decreased	0			
Blood Osmolarity Increased	0			
Blood Potassium Abnormal	0			
Blood Potassium Decreased	0			
Blood Potassium Increased	0			
Crystal Urine Present	0			
Full Blood Count Decreased	0			
Full Blood Count Increased	0			
Gamma-Glutamyltransferase Increased	0			
Haemoglobin Decreased	0			
Hepatic Enzyme Increased	0			
Liver Function Test Increased	0			
Mean Platelet Volume Decreased	0			
Neutrophil Count Decreased	0			
Neutrophil Count Increased	0			
Platelet Count Decreased	0			
Platelet Count Increased	0			
Protein Urine Present	0			
Red Blood Cell Count Increased	0			
Transaminases Increased	0			
Urine Ketone Body Present	0			
White Blood Cell Count Increased	0			
White Blood Cells Urine	0			
White Blood Cells Urine Positive	0			
Hypercalcaemia	0			
Hyperglycaemia	0			
Hypernatraemia	0			
Hypoalbuminaemia	0			
Hypocalcaemia	0			
Hypochloraemia	0			
Hypoglycaemia	0			
Hypokalaemia	0			
Hyponatraemia	0			
Electrolyte Imbalance	0			
Bilirubinuria	0			
Haematuria	0			
Ketonuria	0			
Leukocyturia	0			
Proteinuria	0			
Bandaemia	0			

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants With Coagulation Parameters Reported as AEs

End point title	Number of Participants With Coagulation Parameters Reported as AEs <sup>[6]</sup>
-----------------	---

End point description:

Coagulation parameters included activated partial thromboplastin time (aPTT) and international normalized ratio (INR). Participants with abnormalities in these coagulation parameters recorded as AEs were reported. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11.

End point type	Primary
----------------	---------

End point timeframe:

From Day 1 up to the end of the study (up to 2848 days)

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13	24	65	12
Units: participants				
Activated Partial Thromboplastin Time Prolonged	1	0	1	0
International Normalised Ratio Abnormal	0	0	1	0
International Normalised Ratio Decreased	0	0	1	0
Coagulopathy	0	0	1	0

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	25	42	83
Units: participants				
Activated Partial Thromboplastin Time Prolonged	0	0	0	2
International Normalised Ratio Abnormal	0	0	0	0

International Normalised Ratio Decreased	0	0	0	0
Coagulopathy	0	0	0	0

<b>End point values</b>	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: participants				
Activated Partial Thromboplastin Time Prolonged	0			
International Normalised Ratio Abnormal	0			
International Normalised Ratio Decreased	0			
Coagulopathy	0			

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants With Clinically Significant Shifts in 12 Lead Electrocardiogram (ECG) Results

End point title	Number of Participants With Clinically Significant Shifts in 12 Lead Electrocardiogram (ECG) Results <sup>[7]</sup>
-----------------	---

End point description:

Clinical significance of abnormalities in these parameters was determined based on investigator's discretion. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11.

End point type	Primary
----------------	---------

End point timeframe:

From Day 1 up to the end of the study (up to 2848 days)

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

<b>End point values</b>	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13	22	59	12
Units: participants	2	1	6	1

<b>End point values</b>	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous	Later SMA Onset CS4 Previous ISIS
-------------------------	-----------------------------------	-----------------------------------	------------------------------------	---

			Control	396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	25	42	83
Units: participants	0	0	1	1

<b>End point values</b>	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: participants	0			

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants Taking any Concomitant Medication

End point title	Number of Participants Taking any Concomitant Medication <sup>[8]</sup>
-----------------	---

End point description:

A concomitant therapy is any non-protocol-specified drug or substance (including over-the-counter medications, herbal medications, and vitamin supplements) administered between the beginning of screening and the last telephone contact or study visit. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11.

End point type	Primary
----------------	---------

End point timeframe:

From Day 1 up to the end of the study (up to 2848 days)

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

<b>End point values</b>	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13	24	65	12
Units: participants	13	24	65	12

<b>End point values</b>	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	25	42	83
Units: participants	20	25	42	83



<b>End point values</b>	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: participants	8			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Mean Number of new Motor Milestones Achieved as Assessed by World Health Organization (WHO) Criteria

End point title	Mean Number of new Motor Milestones Achieved as Assessed by World Health Organization (WHO) Criteria
-----------------	--

End point description:

The WHO motor milestones are a set of six milestones in motor development, all of which would be expected to be attained by 24 months of age in healthy children. The individual milestones are: sitting without support, standing with assistance, hands and knees crawling, walking with assistance, standing alone and walking alone. Mean of number of new milestones achieved was calculated and reported in this outcome measure. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11. Here, 'Number of subjects analysed' signifies number of participants with data available for endpoint analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

MMDR Period: At Day 1800

<b>End point values</b>	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	10	43	8
Units: motor milestone				
arithmetic mean (standard deviation)	0.4 (± 0.73)	0.0 (± 0.00)	0.7 (± 1.15)	0.0 (± 0.53)

<b>End point values</b>	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	18	19	45
Units: motor milestone				
arithmetic mean (standard deviation)	-0.6 (± 0.79)	-0.1 (± 0.73)	-0.1 (± 0.32)	-0.2 (± 0.60)

<b>End point values</b>	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: motor milestone				
arithmetic mean (standard deviation)	-0.2 (± 0.75)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants With <2 Years of Age Who Attained Motor Milestones as Assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)

End point title	Percentage of Participants With <2 Years of Age Who Attained Motor Milestones as Assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE) <sup>[9]</sup>
-----------------	---

End point description:

HINE is evaluated in infants between 2-24 months of age. It's a simple, standardized instrument including 26 items assessing different aspects of neurological examinations, such as cranial nerves, posture, movements, tone, and reflexes. In this study, Module 2 of HINE (HINE-2) was assessed, which evaluates 8 developmental milestones (head control, sitting, voluntary grasp, ability to kick, rolling, crawling, standing, and walking) scored on a 3, 4, or 5-point scale, with 0 indicating inability to perform task and score of 2, 3, or 4 indicating full milestone development. Total score is calculated by summing item scores to give maximum possible score of 26. CS3A and CS3B arm/groups were planned to be analysed in this endpoint. Safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen/underwent sham procedure during CS11. Here, 'Number of subjects analysed' signifies number of participants with data available for endpoint analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Last observed visit

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: CS3A and CS3B arms were planned to be analysed for this endpoint.

<b>End point values</b>	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	8	22	62	
Units: percentage of participants				
number (not applicable)				
Head Control:Unable to Maintain Head Upright	13	86	34	
Head Control:Wobbles	13	9	18	
Head Control:All the Time Maintained Upright	75	5	48	
Sitting:Cannot Sit	13	100	39	

Sitting:Sits With Support at Hips	13	0	19	
Sitting:Props	0	0	8	
Sitting:Stable Sit	13	0	19	
Sitting:Pivots (Rotates)	63	0	15	
Voluntary Grasp:No Grasp	0	14	6	
Voluntary Grasp:Uses Whole Hand	0	55	18	
Voluntary Grasp:Index Finger&Thumb;Immature Grasp	0	14	21	
Voluntary Grasp:Pincer Grasp	100	18	52	
Ability to Kick:No Kicking	0	68	18	
Ability to Kick:Kick Horizontally Legs do Not Lift	13	32	29	
Ability to Kick:Upward (Vertically)	0	0	10	
Ability to Kick:Touches Leg	0	0	11	
Ability to Kick:Touches Toes	88	0	32	
Rolling:No Rolling	25	91	27	
Rolling:Rolling to Side	0	9	37	
Rolling:Prone to Supine	13	0	5	
Rolling:Supine to Prone	63	0	31	
Crawling:Does not Lift Head	63	100	81	
Crawling:On Elbow	0	0	13	
Crawling:On Outstretched Hand	0	0	2	
Crawling:Crawling Flat on Abdomen	13	0	3	
Crawling:Crawling on Hands and Knees	25	0	2	
Standing:Does not Support Weight	38	100	79	
Standing:Supports Weight	13	0	11	
Standing:Stands With Support	25	0	10	
Standing:Stands Unaided	25	0	0	
Walking:No Walking	75	100	95	
Walking:Bouncing	0	0	0	
Walking:Cruising (Walks Holding on)	13	0	5	
Walking:Walking Independently	13	0	0	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants who Died or met Permanent Ventilation

End point title	Number of Participants who Died or met Permanent Ventilation
-----------------	--

End point description:

Permanent ventilation was defined as tracheostomy or  $\geq 16$  hours of ventilator support per day continuously for  $>21$  days in the absence of an acute reversible event. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11.

End point type	Secondary
----------------	-----------

End point timeframe:

MMDR Period: Up to Day 1800

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13	24	65	12
Units: participants	0	4	4	1

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	25	42	83
Units: participants	0	0	0	0

End point values	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: participants	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants not Requiring Permanent Ventilation

End point title	Number of Participants not Requiring Permanent Ventilation
-----------------	--

End point description:

The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11.

End point type	Secondary
----------------	-----------

End point timeframe:

MMDR Period: Up to Day 1800

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13	24	65	12
Units: participants	13	20	61	11

<b>End point values</b>	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	25	42	83
Units: participants	20	25	42	83

<b>End point values</b>	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: participants	8			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Motor Function Scale

End point title	Change From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Motor Function Scale <sup>[10]</sup>
-----------------	---

End point description:

The CHOP-INTEND test includes 16 items structured to move from easiest to hardest with the grading including gravity eliminated (lower scores) to antigravity movements (higher scores). All item scores range from 0 (worst) to 4 (best). Total scores range from 0 to 64, with higher scores indicating better movement functioning. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11. Here, 'Number analysed (n)' signifies number of participants with data available for analysis at a specified timepoint. Only CS3A and CS3B arm groups were planned to be analysed for this end point. '99999' signifies that since only one participant was evaluable at Day 2198, standard deviation (SD) was not estimated.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Day 2198

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: CS3A and CS3B arms were planned to be analysed for this endpoint.

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	13	24	65	
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n= 13, 24, 65)	47.4 (± 13.09)	17.3 (± 9.71)	38.8 (± 9.43)	
Change at Day 2198 (n=1, 10, 29)	-6.0 (± 99999)	11.5 (± 12.21)	4.7 (± 14.18)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) Total Score

End point title	Change From Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) Total Score
-----------------	---

End point description:

The HFMSE consists of 33 scored activities used to assess motor function in children with SMA. Participants were asked to do a specific activity (such as rolling) and they were then graded on the quality and execution of that movement on a scale of 0=being unable, 1=performed with some compensation, and 2=unaided. The overall score is the sum of the scores for all activities with a maximum achievable score of 66. If 6 or fewer items are missing, then these items were imputed to be 0 when summing all 33 items. Higher scores indicate increased motor function. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11. Here, 'Subjects analysed' signifies number of participants with data available for endpoint analysis. 'Number analysed (n)' signifies number of participants with data available for analysis at specified timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

MMDR Period: Baseline, MMDR Day 1800

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13	17	49	12
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n= 13, 17, 49, 12, 20, 23, 42, 81, 8)	14.5 (± 13.75)	0.0 (± 0.00)	7.3 (± 6.88)	6.8 (± 6.06)
Change at MMDR Day 1800 (n=10,9,3,8,12,17,19,45,6)	3.4 (± 5.93)	0.4 (± 0.88)	6.0 (± 9.12)	-2.3 (± 3.37)

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous	Later SMA Onset CS4 Previous ISIS
------------------	-----------------------------------	-----------------------------------	------------------------------------	---

			Control	396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	23	42	81
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n= 13, 17, 49, 12, 20, 23, 42, 81, 8)	25.6 (± 14.23)	53.6 (± 8.24)	22.1 (± 7.75)	26.1 (± 10.99)
Change at MMDR Day 1800 (n=10,9,3,8,12,17,19,45,6)	-7.0 (± 6.03)	-2.4 (± 3.41)	-4.7 (± 7.20)	-6.2 (± 6.36)

<b>End point values</b>	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n= 13, 17, 49, 12, 20, 23, 42, 81, 8)	24.5 (± 12.64)			
Change at MMDR Day 1800 (n=10,9,3,8,12,17,19,45,6)	-1.2 (± 9.83)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in Revised Upper Limb Module (RULM) Total Score

End point title	Change from Baseline in Revised Upper Limb Module (RULM) Total Score
-----------------	--

End point description:

RULM Test is used in participants with SMA to assess upper limb functional ability items and has total of 20 items with an entry item that serves as functional class identification and does not contribute to total score. Remaining 19 scorable items reflect different functional domains and graded on 3-point system with score of 0 (unable), 1 (able, with modification), and 2 (able, no difficulty). There is only 1 item that is scored as a can/cannot score, with 1 as the highest score. Scorable items are summed for total score (0-37), higher scores indicating increased upper limb function. Positive change from baseline indicates improvement. Safety analysis set included all participants who were enrolled&received at least 1 dose of nusinersen/underwent sham procedure during CS11. 'Subjects analysed' signifies number of participants with data available for endpoint analysis. 'Number analysed (n)' signifies number of participants with data available for analysis at specified timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

MMDR Period: Baseline, MMDR Day 1800

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	6	18	11
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=11,6,18,11,20,18,42,80,8) Change at MMDR Day 1800 (n=9,3,12,6,13,9,20,45,6)	11.8 (± 7.24) 9.1 (± 4.70)	1.7 (± 1.63) 0.7 (± 0.58)	10.3 (± 6.05) 10.0 (± 5.38)	7.6 (± 6.23) 3.3 (± 5.01)

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	18	42	80
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=11,6,18,11,20,18,42,80,8) Change at MMDR Day 1800 (n=9,3,12,6,13,9,20,45,6)	24.1 (± 6.14) 0.4 (± 3.23)	35.9 (± 1.91) 0.9 (± 1.76)	21.1 (± 4.26) 2.4 (± 3.97)	23.9 (± 5.69) 1.2 (± 3.72)

End point values	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=11,6,18,11,20,18,42,80,8) Change at MMDR Day 1800 (n=9,3,12,6,13,9,20,45,6)	21.4 (± 8.60) 3.2 (± 2.71)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Total Distance Walked Over Time as Assessed by 6-Minute Walk Test (6MWT)

End point title	Change From Baseline in Total Distance Walked Over Time as Assessed by 6-Minute Walk Test (6MWT) <sup>[11]</sup>
-----------------	--

End point description:

The 6MWT measures the distance an individual can walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. Only CS12 Type 2 and CS12 Type 3 arms/ groups were planned to be analysed for this end point. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11. Here, 'Subjects analysed' signifies number of participants with data



available for endpoint analysis. 'Number analysed (n)' signifies number of participants with data available for analysis at specified timepoint. 99999' signifies that since only one participant was evaluable at Day 2670, standard deviation (SD) was not estimated.

End point type	Secondary
End point timeframe:	
Baseline, Day 2670	

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: CS12 Type 2 and CS12 Type 3 arms were planned to be analysed for this endpoint.

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1	13		
Units: meters				
arithmetic mean (standard deviation)	0 (± 99999)	253.3 (± 182.74)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants who Experienced Contracture Assessment

End point title	Number of Participants who Experienced Contracture Assessment
-----------------	---

End point description:

Contracture assessment is performed to assess the motor performance in SMA. The number of participants who experienced at least one contracture at any location and severe contractures in any of the five locations (hip flexors, knee flexors, ankle planter flexors, elbow flexors, forearm flexors) are reported in this outcome measure. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11. Here, 'Number of subjects analysed' signifies number of participants with data available for endpoint analysis.

End point type	Secondary
End point timeframe:	
MMDR Period: At MMDR Day 1800	

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	10	41	8
Units: participant				
At least one contracture at any location	9	10	36	8
Severe contractures in any of the five locations	3	3	16	4

<b>End point values</b>	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13	18	20	45
Units: participant				
At least one contracture at any location	13	8	19	44
Severe contractures in any of the five locations	6	1	9	16

<b>End point values</b>	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	5			
Units: participant				
At least one contracture at any location	5			
Severe contractures in any of the five locations	2			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Compound Muscular Action Potential (CMAP)

End point title	Change From Baseline in Compound Muscular Action Potential (CMAP)
-----------------	---

End point description:

CMAP is an electrophysiological technique that can be used to determine the approximate number of motor neurons in a muscle or group of muscles. Peroneal amplitude (PA) and ulnar amplitude (UA) data is reported in this end point. Score <0 indicated worse response and >0 indicated better response than the normal matched population. Score change <0 indicated worsening and >0 indicated improvement as compared to baseline. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11. Here, 'Number of subjects analysed' signifies number of participants with data available for endpoint analysis. 'Number analysed (n)' signifies number of participants with data available for analysis at specified timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

MMDR Period: Baseline, MMDR Day 1800

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13	22	60	8
Units: millivolt (mV)				
arithmetic mean (standard deviation)				
PA:Baseline (n=13,22,60,8,19,22,31,62,6)	3.02 (± 2.207)	0.35 (± 0.517)	1.91 (± 1.367)	0.94 (± 0.929)
PA:Change at MMDRDay1800 (n=9,5,54,6,7,13,13,28,2)	-0.41 (± 1.290)	0.10 (± 0.243)	0.30 (± 1.395)	0.92 (± 1.901)
UA:Baseline (n=13,12,60,8,20,23,33,62,6)	1.52 (± 1.563)	0.20 (± 0.205)	0.85 (± 0.944)	0.99 (± 0.861)
UA:Change at MMDRDay1800 (n=9,5,35,6,7,14,13,28,2)	0.45 (± 0.837)	0.20 (± 0.188)	0.67 (± 1.261)	0.15 (± 0.436)

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	19	22	31	62
Units: millivolt (mV)				
arithmetic mean (standard deviation)				
PA:Baseline (n=13,22,60,8,19,22,31,62,6)	1.89 (± 1.369)	2.71 (± 1.318)	2.00 (± 2.189)	1.97 (± 1.586)
PA:Change at MMDRDay1800 (n=9,5,54,6,7,13,13,28,2)	-0.59 (± 1.069)	-0.08 (± 1.799)	0.22 (± 4.832)	-0.28 (± 0.924)
UA:Baseline (n=13,12,60,8,20,23,33,62,6)	2.81 (± 1.723)	6.76 (± 2.448)	1.69 (± 1.133)	2.71 (± 2.161)
UA:Change at MMDRDay1800 (n=9,5,35,6,7,14,13,28,2)	0.04 (± 0.957)	0.04 (± 1.641)	0.32 (± 1.127)	0.52 (± 1.60)

End point values	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: millivolt (mV)				
arithmetic mean (standard deviation)				
PA:Baseline (n=13,22,60,8,19,22,31,62,6)	1.35 (± 0.948)			
PA:Change at MMDRDay1800 (n=9,5,54,6,7,13,13,28,2)	0.10 (± 1.414)			
UA:Baseline (n=13,12,60,8,20,23,33,62,6)	1.25 (± 0.935)			
UA:Change at MMDRDay1800 (n=9,5,35,6,7,14,13,28,2)	2.77 (± 2.729)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Body Length

End point title	Change From Baseline in Body Length
-----------------	-------------------------------------

End point description:

Participants were analyzed for change in growth parameter of body length to evaluate clinical efficacy. The body length was calculated using either World Health Organization (WHO) or Centers for Disease Control and Prevention (CDC) scales. The CDC scale allows to calculate the body length up to 20 years, while the WHO scale allows to calculate it only up to 10 years. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11. Here, 'Number of subjects analysed' signifies number of participants with data available for endpoint analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

MMDR Period: Baseline, Day 1800

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	7	14	6
Units: centimetres				
arithmetic mean (standard deviation)	24.2 (± 2.86)	19.9 (± 6.99)	29.4 (± 6.38)	18.8 (± 10.92)

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	1	8	23
Units: centimetres				
arithmetic mean (standard deviation)	18.8 (± 8.54)	23.1 (± 0)	23.7 (± 7.06)	24.6 (± 10.60)

End point values	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	2			
Units: centimetres				
arithmetic mean (standard deviation)	-10.3 (± 57.63)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Weight

End point title	Change From Baseline in Weight
-----------------	--------------------------------

End point description:

Participants were analyzed for change in growth parameter of weight to evaluate clinical efficacy. The weight was calculated using either WHO or CDC scales. The CDC scale allows to calculate the weight up to 20 years, while the WHO scale allows to calculate it only up to 10 years. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11. Here, 'Number of subjects analysed' signifies number of participants with data available for endpoint analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

MMDR Period: Baseline, Day 1800

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	11	43	8
Units: kilograms (kg)				
arithmetic mean (standard deviation)	9.8 (± 3.48)	7.7 (± 4.39)	9.3 (± 3.25)	9.5 (± 7.04)

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13	20	20	50
Units: kilograms (kg)				
arithmetic mean (standard deviation)	15.1 (± 5.96)	13.8 (± 14.88)	15.4 (± 8.05)	15.2 (± 7.38)

End point values	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: kilograms (kg)				
arithmetic mean (standard deviation)	11.7 (± 8.09)			

## Statistical analyses

**Secondary: Change From Baseline in Weight for Age Percentile**

End point title	Change From Baseline in Weight for Age Percentile
-----------------	---

End point description:

Participants who were below the age of 36 months were analyzed for change in growth parameter of weight for age to evaluate clinical efficacy. The weight for age percentile was calculated using either WHO or CDC scales. The CDC scale allows to calculate the weight for age percentile up to 20 years, while the WHO scale allows to calculate it only up to 10 years. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11. Here, 'Number of subjects analysed' signifies number of participants with data available for endpoint analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

MMDR Period: Baseline, Day 1800

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	11	43	6
Units: Percentile				
arithmetic mean (standard deviation)	5.7 (± 27.30)	-5.3 (± 28.97)	0.3 (± 28.55)	-0.7 (± 25.32)

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[12]</sup>	0 <sup>[13]</sup>	9	14
Units: Percentile				
arithmetic mean (standard deviation)	()	()	0.9 (± 17.22)	20.2 (± 28.15)

Notes:

[12] - None of the participants were below the age of 36 months.

[13] - None of the participants were below the age of 36 months.

End point values	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: Percentile				
arithmetic mean (standard deviation)	4.0 (± 33.11)			

**Statistical analyses**

No statistical analyses for this end point

## Secondary: Percentage of CMAP Responders

End point title	Percentage of CMAP Responders
-----------------	-------------------------------

End point description:

CMAP is an electrophysiological technique that can be used to determine the approximate number of motor neurons in a muscle or group of muscles. A participant was defined as a responder if they had a peroneal amplitude  $\geq 1$  mV at last visit (including the amplitude  $\geq 1$  mV at baseline and also demonstrated as such at last visit). The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11. Here, 'Number of subjects analysed' signifies number of participants with data available for endpoint analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

MMDR Period: At Day 1800

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13	22	60	12
Units: percentage of responders				
number (not applicable)	85	0	72	33

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	24	42	81
Units: percentage of responders				
number (not applicable)	65	67	60	51

End point values	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: percentage of responders				
number (not applicable)	25			

## Statistical analyses

No statistical analyses for this end point

**Secondary: Number of Participants who Achieved Motor Milestones**

End point title	Number of Participants who Achieved Motor Milestones
-----------------	--

End point description:

Motor milestones were measured based on WHO criteria. The WHO motor milestones are a set of six milestones in motor development, all of which would be expected to be attained by 24 months of age in healthy children. The individual milestones are: sitting without support (SWS), standing with assistance (SWA), hands and knees crawling (HKC), and walking alone (WA). The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11. Here, 'Number of subjects analysed' signifies number of participants with data available for endpoint analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

MMDR Period: up to Day 1800

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	22	60	12
Units: participants				
SWS:Achieved at Baseline&Maintained to Last Visit	5	0	16	3
SWS:Inability at Baseline, Achieved at Last visit	3	0	11	0
HKC:Achieved at Baseline&Maintained to Last Visit	1	0	0	0
HKC: Inability at Baseline, Achieved at Last Visit	0	0	4	0
SWA:Achieved at Baseline&Maintained to Last Visit	1	0	4	0
SWA:Inability at Baseline, Achieved at Last Visit	0	0	3	0
WA:Achieved at Baseline&Maintained to Last Visit	1	0	0	0
WA:Inability at Baseline, Achieved at Last Visit	0	0	1	0

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	24	42	81
Units: participants				
SWS:Achieved at Baseline&Maintained to Last Visit	13	23	27	58
SWS:Inability at Baseline, Achieved at Last visit	0	0	0	0
HKC:Achieved at Baseline&Maintained to Last Visit	4	20	3	18
HKC: Inability at Baseline, Achieved at Last Visit	0	1	1	2



SWA:Achieved at Baseline&Maintained to Last Visit	1	20	3	3
SWA:Inability at Baseline, Achieved at Last Visit	0	0	0	0
WA:Achieved at Baseline&Maintained to Last Visit	1	16	1	2
WA:Inability at Baseline, Achieved at Last Visit	0	0	0	0

End point values	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: participants				
SWS:Achieved at Baseline&Maintained to Last Visit	5			
SWS:Inability at Baseline, Achieved at Last visit	0			
HKC:Achieved at Baseline&Maintained to Last Visit	2			
HKC: Inability at Baseline, Achieved at Last Visit	1			
SWA:Achieved at Baseline&Maintained to Last Visit	1			
SWA:Inability at Baseline, Achieved at Last Visit	0			
WA:Achieved at Baseline&Maintained to Last Visit	1			
WA:Inability at Baseline, Achieved at Last Visit	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants who Achieved Standing Alone and Walking With Assistance

End point title	Number of Participants who Achieved Standing Alone and Walking With Assistance
-----------------	--

End point description:

Motor milestones were measured based on WHO criteria. The WHO motor milestones are a set of six milestones in motor development, all of which would be expected to be attained by 24 months of age in healthy children. The individual milestones are: sitting without support, standing with assistance, hands and knees crawling, walking with assistance, standing alone and walking alone. Standing alone and walking with assistance was assessed in this outcome measure. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11. Here, 'Number of subjects analysed' signifies number of participants with data available for endpoint analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

MMDR Period: up to Day 1800

<b>End point values</b>	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	22	60	12
Units: participants				
Standing alone	1	0	0	0
Walking with assistance	2	0	3	0

<b>End point values</b>	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	24	42	81
Units: participants				
Standing alone	1	21	2	3
Walking with assistance	3	21	3	7

<b>End point values</b>	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: participants				
Standing alone	3			
Walking with assistance	1			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Total Number of Hospitalizations due to Serious Respiratory Events

End point title	Total Number of Hospitalizations due to Serious Respiratory Events
-----------------	--

End point description:

Total number of hospitalizations is total number of serious events that occurred during study for all participants under each group. For a participant with multiple SAEs which started at the same date and led to hospitalization, it is counted as one hospitalization. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11. Here, 'Number of subjects analysed' signifies number of participants with data available for endpoint analysis. 'Number analysed (n)' signifies number of participants with data available for analysis at specified timepoint.

End point type	Secondary
End point timeframe:	
Up to day 2520	

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13	24	64	12
Units: number of hospitalizations				
number (not applicable)				
Day 1-360 (n=13,24,64,12,20,25,42,83,8)	2	12	30	2
Day 361-720 (n=13,22,61,12,20,25,42,83,8)	2	1	18	1
Day 721-1080 (n=12,22,60,12,19,24,42,81,8)	0	15	12	0
Day 1081-1440 (n=12,21,59,11,18,23,39,78,8)	1	0	4	1
Day 1441-1800 (n=12,18,55,10,18,23,38,76,7)	2	2	2	2
Day 1801-2160 (n=12,16,52,6,18,23,32,71,1)	1	1	7	0
Day 2161-2520 (n= 13,10,39,0,12,20,18,48,0)	0	0	1	0

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	25	42	83
Units: number of hospitalizations				
number (not applicable)				
Day 1-360 (n=13,24,64,12,20,25,42,83,8)	0	0	2	0
Day 361-720 (n=13,22,61,12,20,25,42,83,8)	1	0	2	1
Day 721-1080 (n=12,22,60,12,19,24,42,81,8)	0	0	1	2
Day 1081-1440 (n=12,21,59,11,18,23,39,78,8)	1	0	1	1
Day 1441-1800 (n=12,18,55,10,18,23,38,76,7)	0	0	0	3
Day 1801-2160 (n=12,16,52,6,18,23,32,71,1)	0	0	0	1
Day 2161-2520 (n= 13,10,39,0,12,20,18,48,0)	0	0	0	0

End point values	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: number of hospitalizations				
number (not applicable)				
Day 1-360 (n=13,24,64,12,20,25,42,83,8)	0			
Day 361-720 (n=13,22,61,12,20,25,42,83,8)	0			
Day 721-1080 (n=12,22,60,12,19,24,42,81,8)	0			
Day 1081-1440 (n=12,21,59,11,18,23,39,78,8)	0			
Day 1441-1800 (n=12,18,55,10,18,23,38,76,7)	0			
Day 1801-2160 (n=12,16,52,6,18,23,32,71,1)	0			
Day 2161-2520 (n=13,10,39,0,12,20,18,48,0)	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Total Number of Hospitalizations Due to Serious Adverse Events

End point title	Total Number of Hospitalizations Due to Serious Adverse Events
End point description:	
Total number of hospitalizations is total number of serious events that occurred during study for all participants under each group. For a participant with multiple SAEs which started at the same date and led to hospitalization, it is counted as one hospitalization. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11. Here, 'Number of subjects analysed' signifies number of participants with data available for endpoint analysis. 'Number analysed (n)' signifies number of participants with data available for analysis at specified timepoint.	
End point type	Secondary
End point timeframe:	
Up to day 2520	

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13	24	65	12
Units: number of hospitalizations				
number (not applicable)				
Day 1-360 (n=13,24,65,12,20,25,42,83,8)	6	26	89	12
Day 361-720 (n=13,22,61,12,20,25,42,83,8)	6	19	64	4

Day 721-1080 (n=12,22,60,12,19,24,42,81,8)	5	29	63	7
Day 1081-1440 (n=12,21,59,11,18,23,39,78,8)	2	10	36	4
Day 1441-1800 (n=12,18,55,10,18,23,38,76,7)	4	10	19	3
Day 1801-2160 (n=12,16,52,6,18,23,32,71,1)	1	8	32	0
Day 2161-2520 (n=13,10,39,0,12,20,18,48,0)	0	1	14	0

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	25	42	83
Units: number of hospitalizations				
number (not applicable)				
Day 1-360 (n=13,24,65,12,20,25,42,83,8)	2	0	10	8
Day 361-720 (n=13,22,61,12,20,25,42,83,8)	7	2	10	12
Day 721-1080 (n=12,22,60,12,19,24,42,81,8)	2	0	21	21
Day 1081-1440 (n=12,21,59,11,18,23,39,78,8)	5	1	6	10
Day 1441-1800 (n=12,18,55,10,18,23,38,76,7)	3	0	5	18
Day 1801-2160 (n=12,16,52,6,18,23,32,71,1)	2	2	6	13
Day 2161-2520 (n=13,10,39,0,12,20,18,48,0)	0	0	1	2

End point values	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: number of hospitalizations				
number (not applicable)				
Day 1-360 (n=13,24,65,12,20,25,42,83,8)	3			
Day 361-720 (n=13,22,61,12,20,25,42,83,8)	2			
Day 721-1080 (n=12,22,60,12,19,24,42,81,8)	1			
Day 1081-1440 (n=12,21,59,11,18,23,39,78,8)	3			
Day 1441-1800 (n=12,18,55,10,18,23,38,76,7)	0			
Day 1801-2160 (n=12,16,52,6,18,23,32,71,1)	0			

Day 2161-2520 (n=13,10,39,0,12,20,18,48,0)	0			
---	---	--	--	--

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percent of Time in Hospitalization

End point title	Percent of Time in Hospitalization
-----------------	------------------------------------

End point description:

The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11. Here, 'Number of subjects analysed' signifies number of participants with data available for endpoint analysis. 'Number analysed (n)' signifies number of participants with data available for analysis at specified timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Day 2160

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13	22	60	12
Units: percentage of days				
median (full range (min-max))				
Day 1-360 (n=13,22,60,12,20,24,42,81,8)	0.00 (0.00 to 0.2)	1.11 (0.00 to 16.7)	0.28 (0.00 to 22.8)	0.28 (0.00 to 11.4)
Day 361-720 (n=12,22,60,12,18,24,42,80,8)	0.28 (0.00 to 4.7)	2.08 (0.00 to 17.2)	0.56 (0.00 to 19.2)	0.00 (0.00 to 7.8)
Day 721-1080 (n=12,20,59,12,18,23,39,78,8)	0.00 (0.00 to 1.7)	0.00 (0.00 to 7.5)	0.00 (0.00 to 31.3)	0.00 (0.00 to 20.3)
Day 1081-1440 (n=12,17,54,11,18,23,36,75,8)	0.00 (0.00 to 0.8)	0.00 (0.00 to 7.5)	0.00 (0.00 to 9.7)	0.00 (0.00 to 48.6)
Day 1441-1800 (n=12,15,50,10,17,23,33,80,7)	0.00 (0.00 to 8.3)	0.00 (0.00 to 20.2)	0.00 (0.00 to 22.6)	0.00 (0.00 to 12.1)
Day 1801-2160 (n=7,8,19,6,10,18,9,31,1)	0.00 (0.00 to 0.00)	0.00 (0.00 to 0.00)	0.00 (0.00 to 0.00)	0.00 (0.00 to 0.00)

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	24	42	81
Units: percentage of days				
median (full range (min-max))				

Day 1-360 (n=13,22,60,12,20,24,42,81,8)	0.00 (0.00 to 2.5)	0.00 (0.00 to 0.8)	0.00 (0.00 to 4.4)	0.00 (0.00 to 6.4)
Day 361-720 (n=12,22,60,12,18,24,42,80,8)	0.00 (0.00 to 3.1)	0.00 (0.00 to 0.00)	0.00 (0.00 to 0.00)	0.00 (0.00 to 29.7)
Day 721-1080 (n=12,20,59,12,18,23,39,78,8)	0.00 (0.00 to 6.1)	0.00 (0.00 to 1.4)	0.00 (0.00 to 1.4)	0.00 (0.00 to 12.2)
Day 1081-1440 (n=12,17,54,11,18,23,36,75,8)	0.00 (0.00 to 1.9)	0.00 (0.00 to 0.8)	0.00 (0.00 to 5.8)	0.00 (0.00 to 35.3)
Day 1441-1800 (n=12,15,50,10,17,23,33,80,7)	0.00 (0.00 to 2.0)	0.00 (0.00 to 0.8)	0.00 (0.00 to 5.3)	0.00 (0.00 to 8.9)
Day 1801-2160 (n=7,8,19,6,10,18,9,31,1)	0.00 (0.00 to 0.00)	0.00 (0.00 to 0.00)	0.00 (0.00 to 0.00)	0.00 (0.00 to 0.00)

End point values	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: percentage of days				
median (full range (min-max))				
Day 1-360 (n=13,22,60,12,20,24,42,81,8)	0.00 (0.00 to 2.8)			
Day 361-720 (n=12,22,60,12,18,24,42,80,8)	0.00 (0.00 to 2.5)			
Day 721-1080 (n=12,20,59,12,18,23,39,78,8)	0.00 (0.00 to 11.4)			
Day 1081-1440 (n=12,17,54,11,18,23,36,75,8)	0.69 (0.00 to 1.9)			
Day 1441-1800 (n=12,15,50,10,17,23,33,80,7)	0.00 (0.00 to 1.7)			
Day 1801-2160 (n=7,8,19,6,10,18,9,31,1)	0.00 (0.00 to 0.00)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Cobb-Angle on X-Ray of the Thoracolumbar Spine

End point title	Change From Baseline in Cobb-Angle on X-Ray of the Thoracolumbar Spine
-----------------	--

End point description:

Cobb angle is a measurement of the degree of side-to-side spinal curvature used to define scoliosis. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11. Here, 'Number of subjects analysed' signifies number of participants with data available for endpoint analysis. 'Number analysed (n)' signifies number of participants with data available for analysis at specified timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, MMDR Day 1800

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	11	42	8
Units: degrees				
arithmetic mean (standard deviation)				
BL, n= 8,11,42,8,12,10,35,67,5 Change from BL :MMDRday1800,n=4,4,26,5,4,7,15,30,1	22.7 (± 17.86) 29.8 (± 9.46)	16.6 (± 13.38) 16.9 (± 27.27)	34.8 (± 18.43) 13.0 (± 29.91)	49.2 (± 13.19) -11.6 (± 24.65)

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	10	35	67
Units: degrees				
arithmetic mean (standard deviation)				
BL, n= 8,11,42,8,12,10,35,67,5 Change from BL :MMDRday1800,n=4,4,26,5,4,7,15,30,1	38.5 (± 27.36) -3.8 (± 17.01)	29.8 (± 24.09) 4.0 (± 7.78)	24.3 (± 19.08) 19.8 (± 30.83)	26.8 (± 20.33) 18.8 (± 30.30)

End point values	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	5			
Units: degrees				
arithmetic mean (standard deviation)				
BL, n= 8,11,42,8,12,10,35,67,5 Change from BL :MMDRday1800,n=4,4,26,5,4,7,15,30,1	33.0 (± 16.94) -13.8 (± 0)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Pediatric Quality of Life Inventory (PedsQL) Questionnaires Total Score by Domain

End point title	Pediatric Quality of Life Inventory (PedsQL) Questionnaires Total Score by Domain
-----------------	---



# End point description:

Items on the PedsQL generic core scale are reverse scored and transformed to a 0-100 scale. The PedsQL parent (P) and self (S) reported questionnaire was collected for participants from 2 to 25 years of age. Four dimensions were collected: Physical, Emotional, Social and School functioning and each item was scored on a 5 point ordinal scale. 0 (never) = 100, 1 (almost never) = 75, 2 (sometimes) = 50, 3 (often) = 25, 4 (almost always) = 0. A total score was calculated as the sum of all the items over the number of items answered on all the scales. If more than 50% of items or more were missing, the scale score was not computed. Higher scores indicated better health related quality of life. Safety analysis set. Here, 'Number of subjects analysed' = number of participants with data available for endpoint analysis. 'Number analysed (n)' = number participants with data available for analysis at a specified timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

MMDR Period: At Day 1800

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	6	28	7
Units: score on scale				
arithmetic mean (standard deviation)				
S:Physical Functioning(n=8,6,28,7,8,11,20,50,5)	37.1 (± 11.26)	22.4 (± 31.52)	47.5 (± 25.31)	32.6 (± 20.48)
S:Emotional Functioning(n=8,6,29,7,8,11,20,50,5)	61.9 (± 12.52)	61.7 (± 26.39)	63.3 (± 20.71)	67.4 (± 19.55)
S:Social Functioning(n=8,6,28,7,8,11,20,50,7)	67.5 (± 22.83)	50.8 (± 41.52)	67.1 (± 22.87)	75.7 (± 20.09)
S:School/Work Functioning(n=8,6,28,5,8,11,20,50,5)	54.4 (± 14.25)	40.8 (± 33.23)	66.1 (± 17.66)	71.4 (± 14.64)
P:Physical Functioning(n=8,10,42,7,8,9,20,49,6)	25.0 (± 27.55)	19.1 (± 24.54)	24.9 (± 22.77)	32.6 (± 30.07)
P:Emotional Functioning(n=8,10,42,7,8,9,20,49,6)	68.1 (± 13.08)	69.5 (± 17.23)	58.7 (± 14.90)	65.0 (± 26.46)
P:Social Functioning(n=8,10,42,7,8,9,20,49,6)	47.5 (± 12.82)	50.0 (± 23.66)	51.3 (± 20.06)	64.3 (± 22.63)
P:School/Work Functioning(n=8,11,42,7,8,9,20,49,5)	48.8 (± 12.17)	48.5 (± 31.23)	51.4 (± 21.36)	63.6 (± 18.64)

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	11	20	50
Units: score on scale				
arithmetic mean (standard deviation)				
S:Physical Functioning(n=8,6,28,7,8,11,20,50,5)	39.8 (± 14.54)	52.6 (± 21.28)	45.4 (± 13.85)	39.7 (± 17.97)
S:Emotional Functioning(n=8,6,29,7,8,11,20,50,5)	76.3 (± 15.29)	80.0 (± 18.97)	84.6 (± 15.42)	74.5 (± 22.80)
S:Social Functioning(n=8,6,28,7,8,11,20,50,7)	76.3 (± 10.94)	81.4 (± 10.27)	83.3 (± 15.07)	76.3 (± 13.88)

S:School/Work Functioning(n=8,6,28,5,8,11,20,50,5)	75.6 (± 9.43)	76.4 (± 15.83)	81.8 (± 14.89)	77.1 (± 15.22)
P:Physical Functioning(n=8,10,42,7,8,9,20,49,6)	29.3 (± 16.45)	46.2 (± 76.78)	35.2 (± 18.19)	33.5 (± 18.41)
P:Emotional Functioning(n=8,10,42,7,8,9,20,49,6)	70.0 (± 19.46)	74.4 (± 22.70)	78.0 (± 18.74)	78.2 (± 19.60)
P:Social Functioning(n=8,10,42,7,8,9,20,49,6)	64.4 (± 25.70)	72.2 (± 18.05)	70.0 (± 20.67)	71.0 (± 17.50)
P:School/Work Functioning(n=8,11,42,7,8,9,20,49,5)	76.3 (± 10.94)	77.8 (± 20.78)	78.8 (± 20.19)	78.0 (± 14.75)

End point values	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	5			
Units: score on scale				
arithmetic mean (standard deviation)				
S:Physical Functioning(n=8,6,28,7,8,11,20,50,5)	53.7 (± 24.46)			
S:Emotional Functioning(n=8,6,29,7,8,11,20,50,5)	67.0 (± 16.43)			
S:Social Functioning(n=8,6,28,7,8,11,20,50,7)	80.0 (± 12.25)			
S:School/Work Functioning(n=8,6,28,5,8,11,20,50,5)	82.0 (± 11.51)			
P:Physical Functioning(n=8,10,42,7,8,9,20,49,6)	20.8 (± 5.82)			
P:Emotional Functioning(n=8,10,42,7,8,9,20,49,6)	74.2 (± 11.14)			
P:Social Functioning(n=8,10,42,7,8,9,20,49,6)	60.8 (± 13.20)			
P:School/Work Functioning(n=8,11,42,7,8,9,20,49,5)	79.2 (± 9.70)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Assessment of Caregiver Experience with Neuromuscular Disease (ACEND) Questionnaire Total Score

End point title	Change From Baseline in Assessment of Caregiver Experience with Neuromuscular Disease (ACEND) Questionnaire Total Score
-----------------	---

End point description:

The ACEND is a questionnaire that includes a total of seven domains assessing physical impact (including feeding/grooming/dressing, sitting/play, transfers, and mobility) and general caregiver impact (including time, emotion, and finance) and each domain comprises several items. The total score (TS) for each domain will be calculated on a scale of 0 to 100. Higher scores indicate a greater impact on the caregiver. The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11. Here, 'Number of subjects analysed' signifies number of participants with data available for endpoint analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

MMDR Period: Baseline, MMDR Day 1800

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	11	38	8
Units: score on scale				
arithmetic mean (standard deviation)				
Feeding/Grooming/Dressing TS: Change MMDRDay1800	14.2 (± 21.56)	0.6 (± 2.01)	18.5 (± 22.07)	9.2 (± 15.91)
Sitting/Play TS: Change at MMDR Day 1800	0.8 (± 10.29)	-0.4 (± 14.91)	5.5 (± 28.01)	1.5 (± 22.21)
Transfers TS: Change at MMDR Day 1800	0.4 (± 7.24)	0.7 (± 1.62)	0.0 (± 12.32)	-5.5 (± 6.68)
Mobility TS: Change at MMDR Day 1800	-2.3 (± 14.93)	0.5 (± 1.72)	7.5 (± 22.52)	-12.1 (± 18.69)
Time TS: Change at MMDR Day 1800	4.4 (± 19.78)	6.8 (± 24.76)	-0.7 (± 22.60)	-6.3 (± 21.65)
Emotion TS: Change at MMDR Day 1800	5.0 (± 14.80)	6.3 (± 15.82)	-2.1 (± 20.98)	2.1 (± 14.22)
Finance TS: Change at MMDR Day 1800	-1.0 (± 17.29)	7.3 (± 20.66)	-4.1 (± 22.17)	4.4 (± 18.98)

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	9	18	47
Units: score on scale				
arithmetic mean (standard deviation)				
Feeding/Grooming/Dressing TS: Change MMDRDay1800	8.3 (± 11.55)	-0.4 (± 1.11)	4.6 (± 18.90)	5.9 (± 12.07)
Sitting/Play TS: Change at MMDR Day 1800	1.0 (± 8.21)	0.0 (± 0.00)	-1.8 (± 16.48)	1.7 (± 16.08)
Transfers TS: Change at MMDR Day 1800	-6.4 (± 10.98)	0.4 (± 3.71)	-3.6 (± 16.17)	1.2 (± 18.16)
Mobility TS: Change at MMDR Day 1800	-9.6 (± 12.49)	-2.5 (± 6.14)	1.9 (± 18.47)	-5.8 (± 17.50)
Time TS: Change at MMDR Day 1800	-1.6 (± 21.33)	-2.1 (± 12.10)	1.4 (± 17.22)	0.5 (± 16.78)
Emotion TS: Change at MMDR Day 1800	-2.8 (± 26.23)	1.2 (± 12.96)	4.7 (± 12.73)	-2.5 (± 12.70)
Finance TS: Change at MMDR Day 1800	1.9 (± 24.49)	1.1 (± 8.94)	7.2 (± 17.92)	2.1 (± 19.94)

End point values	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: score on scale				

arithmetic mean (standard deviation)				
Feeding/Grooming/Dressing TS: Change MMDR Day 1800	2.8 ( $\pm$ 7.72)			
Sitting/Play TS: Change at MMDR Day 1800	-2.0 ( $\pm$ 4.90)			
Transfers TS: Change at MMDR Day 1800	-4.0 ( $\pm$ 11.03)			
Mobility TS: Change at MMDR Day 1800	6.7 ( $\pm$ 20.66)			
Time TS: Change at MMDR Day 1800	-6.3 ( $\pm$ 14.25)			
Emotion TS: Change at MMDR Day 1800	-18.1 ( $\pm$ 12.01)			
Finance TS: Change at MMDR Day 1800	-3.3 ( $\pm$ 8.16)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Disease-related Hospitalizations and AEs

End point title	Number of Participants With Disease-related Hospitalizations and AEs
End point description: The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11.	
End point type	Secondary
End point timeframe: MMDR Period: up to Day 1800	

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13	24	65	12
Units: participants				
Disease-related hospitalization	6	9	27	5
Disease-related AEs	11	21	60	7

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	25	42	83
Units: participants				
Disease-related hospitalization	9	0	13	23
Disease-related AEs	16	12	36	68

End point values	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: participants				
Disease-related hospitalization	1			
Disease-related AEs	8			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Survival Rate

End point title	Survival Rate
End point description: All dosed population included all participants who received a dose of nusinersen or were in the sham treatment group.	
End point type	Secondary
End point timeframe: MMDR Period: up to Day 1800	

End point values	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443	Infantile SMA Onset 232SM202
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	13	24	65	12
Units: percentage of participants				
number (not applicable)	100	79.16	87.69	91.66

End point values	Later SMA Onset CS12 Type 2	Later SMA Onset CS12 Type 3	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	25	42	83
Units: percentage of participants				
number (not applicable)	100	100	97.61	98.79

<b>End point values</b>	Later SMA Onset 232SM202			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: percentage of participants				
number (not applicable)	100			

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From Day 1 up to the end of the study (up to 2848 days)

Adverse event reporting additional description:

The safety analysis set included all participants who were enrolled and received at least 1 dose of nusinersen or underwent sham procedure during CS11.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.0
--------------------	------

### Reporting groups

Reporting group title	Infantile SMA Onset CS3A
-----------------------	--------------------------

Reporting group description:

Participants who received nusinersen in study ISIS 396443-CS3A, in an open-label period, received maintenance doses of nusinersen, intrathecal (IT) injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.

Reporting group title	Infantile SMA Onset CS3B Previous Control
-----------------------	---

Reporting group description:

Participants who received sham procedures in study ISIS 396443-CS3B, in a double-blind period, received 4 loading doses of nusinersen IT injection on Days 1, 15, 29, and 64 followed by maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.

Reporting group title	Infantile SMA Onset CS3B Previous ISIS 396443
-----------------------	---

Reporting group description:

Participants who received nusinersen in study ISIS 396443-CS3B, in the double-blind period, received 3 sham procedures on Days 1, 15, and 64 and 1 loading dose of nusinersen IT injection on Day 29 followed by maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.

Reporting group title	Infantile SMA Onset 232SM202
-----------------------	------------------------------

Reporting group description:

Participants who received nusinersen in study 232SM202 (i.e., Part 2) in an open-label period, received maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.

Reporting group title	Later SMA Onset 232SM202
-----------------------	--------------------------

Reporting group description:

Participants who received nusinersen in study 232SM202 (i.e., Part 2) in an open-label period, received maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.

Reporting group title	Later SMA Onset CS12 Type 3
-----------------------	-----------------------------

Reporting group description:

Participants who received nusinersen in study ISIS 396443-CS12 in an open-label period, received maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.

Reporting group title	Later SMA Onset CS12 Type 2
-----------------------	-----------------------------

Reporting group description:

Participants who received nusinersen in study ISIS 396443-CS12 in an open-label period, received maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.

Reporting group title	Later SMA Onset CS4 Previous Control
-----------------------	--------------------------------------

Reporting group description:

Participants who received sham procedures in the study ISIS 396443-CS4 in a double-blind period received 3 loading doses of nusinersen administered by IT injection on Days 1, 29, and 85 followed by maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.

Reporting group title	Later SMA Onset CS4 Previous ISIS 396443
Reporting group description:	
Participants who received nusinersen in the study ISIS 396443-CS4 in a double-blind period received 2 loading doses of nusinersen administered by IT injection on Days 1 and 85 and 1 sham procedure on Day 29 followed by maintenance doses of nusinersen IT injection, on days 1, 120, 240, 360, 480, 600, 720, 840, 960, 1080, 1200, 1320, 1440, 1560, and 1680 in MMDR period of this study.	

<b>Serious adverse events</b>	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443
Total subjects affected by serious adverse events			
subjects affected / exposed	11 / 13 (84.62%)	23 / 24 (95.83%)	59 / 65 (90.77%)
number of deaths (all causes)	0	5	8
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Brain stem glioma			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hair follicle tumour benign			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypotension			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypovolaemic shock			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Positive airway pressure therapy			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration			



site conditions			
Death			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Complication of device insertion			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complication associated with device			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired healing			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical device discomfort			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised oedema			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Discomfort			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	3 / 65 (4.62%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			

subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Immune system disorders			
Cytokine storm			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaphylactic reaction			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Testicular torsion			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory distress syndrome			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	3 / 13 (23.08%)	9 / 24 (37.50%)	15 / 65 (23.08%)
occurrences causally related to treatment / all	0 / 3	0 / 26	0 / 29
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Adenoidal hypertrophy			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Apnoea			

subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Atelectasis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	5 / 65 (7.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial hyperreactivity			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic respiratory failure			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial secretion retention			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive airways disorder			

subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive sleep apnoea syndrome			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	3 / 65 (4.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory arrest			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pneumothorax			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	3 / 65 (4.62%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			

subjects affected / exposed	2 / 13 (15.38%)	5 / 24 (20.83%)	9 / 65 (13.85%)
occurrences causally related to treatment / all	0 / 2	0 / 7	0 / 11
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 13 (0.00%)	3 / 24 (12.50%)	9 / 65 (13.85%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 10
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Respiratory symptom			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sputum increased			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachypnoea			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract inflammation			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicidal ideation			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device malfunction			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device mechanical issue			

subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device failure			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood culture positive			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovirus test positive			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronavirus test positive			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Human rhinovirus test positive			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory rate increased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oxygen saturation decreased			
subjects affected / exposed	0 / 13 (0.00%)	4 / 24 (16.67%)	3 / 65 (4.62%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Respiratory syncytial virus test positive			

subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rubulavirus test positive			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Accident			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Face injury			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foreign body aspiration			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrostomy tube site complication			

subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal stoma complication			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal procedural complication			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foreign body in respiratory tract			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint dislocation			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb injury			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal procedural complication			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurological procedural complication			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post lumbar puncture syndrome			



subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural complication			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative ileus			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural pain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural dizziness			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract procedural complication			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Unintentional medical device removal			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			

subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Cryptorchism			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal muscular atrophy			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Laryngeal cleft			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Developmental hip dysplasia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Talipes			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac arrest			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	3 / 65 (4.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cardio-respiratory arrest			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	3 / 65 (4.62%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 2
Supraventricular extrasystoles			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wolff-parkinson-white syndrome			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Altered state of consciousness			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Status epilepticus			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxic-ischaemic encephalopathy			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Brain hypoxia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			

subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ulcerative			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acetonaemic vomiting			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			

subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dental caries			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cyclic vomiting syndrome			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis haemorrhagic			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	3 / 65 (4.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gingival hypertrophy			

subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus hernia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	3 / 65 (4.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			

subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	5 / 65 (7.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash papular			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot deformity			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hip deformity			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pathological fracture			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuromuscular scoliosis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kyphoscoliosis			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	4 / 65 (6.15%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint contracture			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retrognathia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scoliosis			
subjects affected / exposed	2 / 13 (15.38%)	0 / 24 (0.00%)	10 / 65 (15.38%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 11
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abdominal sepsis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute sinusitis			



subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenovirus infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	3 / 65 (4.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis perforated			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis staphylococcal			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis pneumococcal			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	4 / 65 (6.15%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			

subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronavirus infection			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	3 / 65 (4.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronavirus pneumonia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Covid-19			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	3 / 65 (4.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Covid-19 pneumonia			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovirus infection			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	6 / 65 (9.23%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia infection			

subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	4 / 65 (6.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis viral			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis adenovirus			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Human bocavirus infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemophilus infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incision site abscess			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal sepsis			

subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	3 / 65 (4.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection viral			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	7 / 65 (10.77%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 16
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasopharyngitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metapneumovirus infection			
subjects affected / exposed	1 / 13 (7.69%)	2 / 24 (8.33%)	4 / 65 (6.15%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical device site abscess			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis chronic			

subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media acute			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media chronic			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parainfluenzae virus infection			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	6 / 65 (9.23%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periorbital cellulitis			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumococcal bacteraemia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngotonsillitis			

subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis streptococcal			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	3 / 13 (23.08%)	8 / 24 (33.33%)	27 / 65 (41.54%)
occurrences causally related to treatment / all	0 / 5	0 / 15	0 / 44
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	6 / 65 (9.23%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	4 / 65 (6.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia haemophilus			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia influenzal			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia moraxella			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia mycoplasmal			

subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia parainfluenzae viral			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	3 / 65 (4.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia serratia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	3 / 65 (4.62%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia respiratory syncytial viral			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pseudomonal			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	3 / 65 (4.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia streptococcal			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonas bronchitis			

subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	4 / 65 (6.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	12 / 65 (18.46%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 13
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonas infection			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	3 / 65 (4.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulpitis dental			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyuria			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	8 / 65 (12.31%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 17
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection viral			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinovirus infection			



subjects affected / exposed	0 / 13 (0.00%)	5 / 24 (20.83%)	5 / 65 (7.69%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 12
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotavirus infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal bacteraemia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stenotrophomonas infection			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stoma site infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			

subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 13 (0.00%)	3 / 24 (12.50%)	5 / 65 (7.69%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral pericarditis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	2 / 13 (15.38%)	1 / 24 (4.17%)	3 / 65 (4.62%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			

subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	3 / 65 (4.62%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Feeding intolerance			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	4 / 65 (6.15%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malnutrition			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ketoacidosis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic acidosis			

subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Infantile SMA Onset 232SM202	Later SMA Onset 232SM202	Later SMA Onset CS12 Type 3
Total subjects affected by serious adverse events			
subjects affected / exposed	9 / 12 (75.00%)	5 / 8 (62.50%)	6 / 25 (24.00%)
number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Brain stem glioma			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hair follicle tumour benign			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypovolaemic shock			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Positive airway pressure therapy			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Death			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complication of device insertion			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complication associated with device			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired healing			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical device discomfort			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised oedema			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Discomfort			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Cytokine storm			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaphylactic reaction			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Testicular torsion			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory distress syndrome			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	2 / 12 (16.67%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Adenoidal hypertrophy			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Apnoea			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atelectasis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial hyperreactivity			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic respiratory failure			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial secretion retention			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive airways disorder			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive sleep apnoea syndrome			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory arrest			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			



subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory symptom			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sputum increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachypnoea			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract inflammation			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicidal ideation			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	1 / 25 (4.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device malfunction			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device mechanical issue			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device failure			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood culture positive			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovirus test positive			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronavirus test positive			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Human rhinovirus test positive			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory rate increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oxygen saturation decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus test positive			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rubulavirus test positive			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Accident			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Face injury			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	1 / 12 (8.33%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	1 / 12 (8.33%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foreign body aspiration			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrostomy tube site complication			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal stoma complication			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal procedural complication			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foreign body in respiratory tract			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint dislocation			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb injury			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal procedural complication			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurological procedural complication			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	1 / 25 (4.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post lumbar puncture syndrome			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	2 / 25 (8.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural complication			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative ileus			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural dizziness			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract procedural complication			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Unintentional medical device removal			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Cryptorchism			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal muscular atrophy			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal cleft			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Developmental hip dysplasia			
subjects affected / exposed	0 / 12 (0.00%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Talipes			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac arrest			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cardio-respiratory arrest			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular extrasystoles			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wolff-parkinson-white syndrome			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Altered state of consciousness			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Status epilepticus			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxic-ischaemic encephalopathy			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain hypoxia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			

subjects affected / exposed	0 / 12 (0.00%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ulcerative			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acetonaemic vomiting			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			



subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dental caries			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cyclic vomiting syndrome			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis haemorrhagic			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gingival hypertrophy			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus hernia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	1 / 25 (4.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash papular			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	1 / 25 (4.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot deformity			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hip deformity			
subjects affected / exposed	0 / 12 (0.00%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pathological fracture			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuromuscular scoliosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kyphoscoliosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint contracture			
subjects affected / exposed	0 / 12 (0.00%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retrognathia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scoliosis			
subjects affected / exposed	3 / 12 (25.00%)	2 / 8 (25.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abdominal sepsis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute sinusitis			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenovirus infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis perforated			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis staphylococcal			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis pneumococcal			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronavirus infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronavirus pneumonia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Covid-19			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Covid-19 pneumonia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovirus infection			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia infection			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis viral			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis adenovirus			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Human bocavirus infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemophilus infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incision site abscess			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal sepsis			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection viral			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasopharyngitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metapneumovirus infection			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical device site abscess			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis chronic			



subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media acute			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media chronic			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parainfluenzae virus infection			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periorbital cellulitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumococcal bacteraemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngotonsillitis			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis streptococcal			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	5 / 12 (41.67%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia haemophilus			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia influenzal			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia moraxella			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia mycoplasmal			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia parainfluenzae viral			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia serratia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia respiratory syncytial viral			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pseudomonal			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia streptococcal			
subjects affected / exposed	0 / 12 (0.00%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonas bronchitis			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonas infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulpitis dental			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyuria			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	1 / 25 (4.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection viral			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinovirus infection			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotavirus infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal bacteraemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stenotrophomonas infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stoma site infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral pericarditis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			

subjects affected / exposed	2 / 12 (16.67%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Feeding intolerance			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malnutrition			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ketoacidosis			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic acidosis			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Later SMA Onset CS12 Type 2	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Total subjects affected by serious adverse events			
subjects affected / exposed	12 / 20 (60.00%)	26 / 42 (61.90%)	47 / 83 (56.63%)
number of deaths (all causes)	0	1	1
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Brain stem glioma			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hair follicle tumour benign			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypovolaemic shock			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Positive airway pressure therapy			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Death			



subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complication of device insertion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complication associated with device			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired healing			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical device discomfort			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised oedema			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Discomfort			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Cytokine storm			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaphylactic reaction			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Testicular torsion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory distress syndrome			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Acute respiratory failure			
subjects affected / exposed	2 / 20 (10.00%)	3 / 42 (7.14%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Adenoidal hypertrophy			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Apnoea			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atelectasis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	2 / 83 (2.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial hyperreactivity			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic respiratory failure			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial secretion retention			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive airways disorder			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive sleep apnoea syndrome			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory arrest			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			

subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory symptom			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sputum increased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachypnoea			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract inflammation			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicidal ideation			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device malfunction			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device mechanical issue			

subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device failure			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood culture positive			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovirus test positive			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronavirus test positive			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Human rhinovirus test positive			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory rate increased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oxygen saturation decreased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus test positive			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rubulavirus test positive			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Accident			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Face injury			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	3 / 83 (3.61%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	2 / 83 (2.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 20 (0.00%)	2 / 42 (4.76%)	3 / 83 (3.61%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foreign body aspiration			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrostomy tube site complication			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal stoma complication			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal procedural complication			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foreign body in respiratory tract			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint dislocation			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb injury			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal procedural complication			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurological procedural complication			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post lumbar puncture syndrome			



subjects affected / exposed	0 / 20 (0.00%)	2 / 42 (4.76%)	4 / 83 (4.82%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural complication			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative ileus			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	2 / 83 (2.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural dizziness			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract procedural complication			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Unintentional medical device removal			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			

subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Cryptorchism			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal muscular atrophy			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal cleft			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Developmental hip dysplasia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	2 / 83 (2.41%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Talipes			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac arrest			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cardio-respiratory arrest			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular extrasystoles			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wolff-parkinson-white syndrome			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Altered state of consciousness			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Status epilepticus			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxic-ischaemic encephalopathy			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain hypoxia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ulcerative			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acetonaemic vomiting			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dental caries			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cyclic vomiting syndrome			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis haemorrhagic			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gingival hypertrophy			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus hernia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash papular			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot deformity			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	3 / 83 (3.61%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hip deformity			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pathological fracture			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuromuscular scoliosis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kyphoscoliosis			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	2 / 83 (2.41%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint contracture			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retrognathia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scoliosis			
subjects affected / exposed	6 / 20 (30.00%)	11 / 42 (26.19%)	22 / 83 (26.51%)
occurrences causally related to treatment / all	0 / 6	0 / 11	0 / 22
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abdominal sepsis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute sinusitis			



subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenovirus infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis perforated			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis staphylococcal			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis pneumococcal			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	2 / 83 (2.41%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronavirus infection			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronavirus pneumonia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Covid-19			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Covid-19 pneumonia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovirus infection			
subjects affected / exposed	0 / 20 (0.00%)	3 / 42 (7.14%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia infection			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 20 (0.00%)	2 / 42 (4.76%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis viral			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis adenovirus			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 20 (0.00%)	2 / 42 (4.76%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Human bocavirus infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemophilus infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incision site abscess			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal sepsis			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	3 / 83 (3.61%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection viral			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasopharyngitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metapneumovirus infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical device site abscess			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis chronic			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media acute			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media chronic			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parainfluenzae virus infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periorbital cellulitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumococcal bacteraemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngotonsillitis			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis streptococcal			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	2 / 20 (10.00%)	8 / 42 (19.05%)	6 / 83 (7.23%)
occurrences causally related to treatment / all	0 / 2	0 / 12	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia haemophilus			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia influenzal			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia moraxella			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia mycoplasmal			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia parainfluenzae viral			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia serratia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia respiratory syncytial viral			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pseudomonal			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	1 / 20 (5.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia streptococcal			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonas bronchitis			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 20 (0.00%)	4 / 42 (9.52%)	3 / 83 (3.61%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonas infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulpitis dental			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyuria			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection viral			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinovirus infection			



subjects affected / exposed	1 / 20 (5.00%)	2 / 42 (4.76%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotavirus infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal bacteraemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stenotrophomonas infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stoma site infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			

subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	2 / 83 (2.41%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral pericarditis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			

subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Feeding intolerance			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malnutrition			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ketoacidosis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic acidosis			

subjects affected / exposed	0 / 20 (0.00%)	2 / 42 (4.76%)	0 / 83 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Infantile SMA Onset CS3A	Infantile SMA Onset CS3B Previous Control	Infantile SMA Onset CS3B Previous ISIS 396443
Total subjects affected by non-serious adverse events			
subjects affected / exposed	13 / 13 (100.00%)	23 / 24 (95.83%)	65 / 65 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Skin papilloma			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Hair follicle tumour benign			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	0	0	1
Hypotension			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	3 / 65 (4.62%)
occurrences (all)	0	0	3
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	5 / 65 (7.69%)
occurrences (all)	0	2	5
Developmental delay			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	4 / 65 (6.15%)
occurrences (all)	0	0	4
Gait disturbance			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Infusion site bruising			

subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Medical device site haemorrhage			
subjects affected / exposed	2 / 13 (15.38%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	2	0	0
Non-cardiac chest pain			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Peripheral swelling			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences (all)	1	0	2
Pneumatosi			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	13 / 13 (100.00%)	15 / 24 (62.50%)	50 / 65 (76.92%)
occurrences (all)	66	76	252
Pain			
subjects affected / exposed	2 / 13 (15.38%)	3 / 24 (12.50%)	3 / 65 (4.62%)
occurrences (all)	2	3	3
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	1 / 65 (1.54%)
occurrences (all)	0	2	1
Multiple allergies			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Seasonal allergy			
subjects affected / exposed	0 / 13 (0.00%)	3 / 24 (12.50%)	9 / 65 (13.85%)
occurrences (all)	0	5	9
Reproductive system and breast disorders			
Heavy menstrual bleeding			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Testicular atrophy			

subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 24 (0.00%) 0	0 / 65 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	1 / 24 (4.17%) 2	4 / 65 (6.15%) 4
Adenoidal hypertrophy subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 24 (0.00%) 0	3 / 65 (4.62%) 5
Aspiration subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 24 (4.17%) 1	5 / 65 (7.69%) 7
Asthma subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	0 / 65 (0.00%) 0
Atelectasis subjects affected / exposed occurrences (all)	5 / 13 (38.46%) 6	2 / 24 (8.33%) 2	9 / 65 (13.85%) 12
Bronchial wall thickening subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 24 (0.00%) 0	0 / 65 (0.00%) 0
Chronic respiratory failure subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	3 / 24 (12.50%) 3	0 / 65 (0.00%) 0
Epiglottic oedema subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	1 / 65 (1.54%) 1
Emphysema subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 24 (0.00%) 0	0 / 65 (0.00%) 0
Dyspnoea subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	2 / 24 (8.33%) 2	3 / 65 (4.62%) 4
Cough			

subjects affected / exposed	4 / 13 (30.77%)	4 / 24 (16.67%)	16 / 65 (24.62%)
occurrences (all)	15	5	30
Epistaxis			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	11 / 65 (16.92%)
occurrences (all)	1	1	14
Increased upper airway secretion			
subjects affected / exposed	0 / 13 (0.00%)	3 / 24 (12.50%)	6 / 65 (9.23%)
occurrences (all)	0	5	8
Increased viscosity of upper respiratory secretion			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences (all)	1	0	2
Increased bronchial secretion			
subjects affected / exposed	2 / 13 (15.38%)	4 / 24 (16.67%)	8 / 65 (12.31%)
occurrences (all)	2	4	13
Hypoxia			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	4 / 65 (6.15%)
occurrences (all)	1	1	5
Laryngospasm			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract congestion			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	4 / 65 (6.15%)
occurrences (all)	0	0	5
Nasal congestion			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	6 / 65 (9.23%)
occurrences (all)	1	0	11
Lung infiltration			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	1 / 65 (1.54%)
occurrences (all)	1	1	1
Pleural effusion			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences (all)	1	1	0
Obstructive sleep apnoea syndrome			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences (all)	0	0	2

Obstructive airways disorder subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	1 / 24 (4.17%) 1	0 / 65 (0.00%) 0
Noninfective bronchitis subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 24 (4.17%) 1	0 / 65 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	1 / 24 (4.17%) 1	3 / 65 (4.62%) 4
Respiratory disorder subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 24 (0.00%) 0	3 / 65 (4.62%) 4
Rales subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 24 (0.00%) 0	0 / 65 (0.00%) 0
Pulmonary oedema subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	0 / 65 (0.00%) 0
Productive cough subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	3 / 65 (4.62%) 3
Respiratory distress subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	5 / 24 (20.83%) 8	5 / 65 (7.69%) 6
Rhinorrhoea subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 3	2 / 24 (8.33%) 2	7 / 65 (10.77%) 10
Rhinitis allergic subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	3 / 24 (12.50%) 3	1 / 65 (1.54%) 1
Restrictive pulmonary disease subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 24 (4.17%) 1	1 / 65 (1.54%) 1
Tonsillar hypertrophy subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	4 / 65 (6.15%) 6



Tachypnoea			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	0	0	2
Sputum discoloured			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences (all)	2	1	0
Sleep apnoea syndrome			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	1 / 65 (1.54%)
occurrences (all)	0	2	1
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences (all)	0	0	2
Agitation			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	1 / 65 (1.54%)
occurrences (all)	1	1	1
Anxiety disorder			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Attention deficit hyperactivity disorder			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	1 / 65 (1.54%)
occurrences (all)	1	1	1
Panic attack			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Mental status changes			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Learning disability			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Irritability			

subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	2 / 24 (8.33%) 5	4 / 65 (6.15%) 4
Insomnia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	2 / 24 (8.33%) 3	0 / 65 (0.00%) 0
Encopresis subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	0 / 65 (0.00%) 0
Depression subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	0 / 65 (0.00%) 0
Product issues Device malfunction subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	1 / 65 (1.54%) 1
Device dislocation subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 24 (0.00%) 0	5 / 65 (7.69%) 10
Investigations Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 24 (0.00%) 0	1 / 65 (1.54%) 1
Blood albumin decreased subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	0 / 65 (0.00%) 0
Blood iron decreased subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	3 / 65 (4.62%) 3
Blood potassium decreased subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	0 / 65 (0.00%) 0
Bone density decreased subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	1 / 24 (4.17%) 1	1 / 65 (1.54%) 1
Breath sounds abnormal			

subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	2	0	1
Cardiac murmur			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Clostridium test positive			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	0 / 65 (0.00%)
occurrences (all)	0	2	0
Heart rate increased			
subjects affected / exposed	3 / 13 (23.08%)	2 / 24 (8.33%)	4 / 65 (6.15%)
occurrences (all)	4	2	4
Electrocardiogram qt prolonged			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	1	0	1
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	3 / 65 (4.62%)
occurrences (all)	0	2	3
Haemoglobin decreased			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	2 / 65 (3.08%)
occurrences (all)	0	1	2
Crystal urine present			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Oxygen consumption decreased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Occult blood positive			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	0	0	1
Mean platelet volume decreased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Oxygen saturation decreased			
subjects affected / exposed	1 / 13 (7.69%)	7 / 24 (29.17%)	18 / 65 (27.69%)
occurrences (all)	2	9	32

Qrs axis abnormal			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Pseudomonas test positive			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	6 / 65 (9.23%)
occurrences (all)	0	1	7
Prothrombin time prolonged			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Platelet count increased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Red blood cell count increased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Red blood cell sedimentation rate increased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Sars-cov-2 test positive			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	1	0	1
Vitamin d decreased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
White blood cells urine positive			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Weight increased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	3 / 65 (4.62%)
occurrences (all)	0	0	3
Von willebrand\'s factor activity decreased			

subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
White blood cell count increased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	4 / 65 (6.15%)
occurrences (all)	0	0	4
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	0	0	1
Arthropod bite			
subjects affected / exposed	2 / 13 (15.38%)	1 / 24 (4.17%)	3 / 65 (4.62%)
occurrences (all)	2	1	3
Concussion			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	0	0	1
Anaesthetic complication neurological			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Anaesthetic complication			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Accident			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	1	0	1
Femur fracture			
subjects affected / exposed	2 / 13 (15.38%)	3 / 24 (12.50%)	5 / 65 (7.69%)
occurrences (all)	2	4	7
Fibula fracture			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	0	0	1
Gastrointestinal stoma complication			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Humerus fracture			

subjects affected / exposed	3 / 13 (23.08%)	1 / 24 (4.17%)	1 / 65 (1.54%)
occurrences (all)	3	1	1
Fall			
subjects affected / exposed	1 / 13 (7.69%)	3 / 24 (12.50%)	6 / 65 (9.23%)
occurrences (all)	1	3	7
Incision site swelling			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Endotracheal intubation complication			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	0	0	1
Extraskkeletal ossification			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Immunisation reaction			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	0	0	1
Post procedural contusion			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	1	0	1
Post procedural constipation			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	5 / 65 (7.69%)
occurrences (all)	0	0	8
Post procedural complication			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	1 / 65 (1.54%)
occurrences (all)	1	1	1
Post lumbar puncture syndrome			
subjects affected / exposed	2 / 13 (15.38%)	4 / 24 (16.67%)	4 / 65 (6.15%)
occurrences (all)	2	4	4
Palate injury			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Lower limb fracture			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences (all)	0	1	0
Post procedural haemorrhage			

subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	3 / 65 (4.62%)
occurrences (all)	1	1	3
Ligament sprain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Joint dislocation			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	7 / 65 (10.77%)
occurrences (all)	2	1	7
Post procedural inflammation			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Procedural hypotension			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	5 / 13 (38.46%)	5 / 24 (20.83%)	15 / 65 (23.08%)
occurrences (all)	6	6	30
Procedural pneumothorax			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Procedural vomiting			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	1	0	1
Respiratory tract procedural complication			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	0	0	1
Skin abrasion			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences (all)	1	0	2
Stoma site discharge			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	0	0	1
Stoma site erythema			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	2 / 65 (3.08%)
occurrences (all)	0	4	2

Stoma site haemorrhage subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	2 / 24 (8.33%) 2	2 / 65 (3.08%) 2
Stoma site hypergranulation subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	4 / 24 (16.67%) 5	5 / 65 (7.69%) 5
Suture rupture subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	0 / 65 (0.00%) 0
Tibia fracture subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 24 (0.00%) 0	2 / 65 (3.08%) 3
Tooth fracture subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	0 / 65 (0.00%) 0
Wound dehiscence subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	0 / 65 (0.00%) 0
Wound secretion subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	0 / 65 (0.00%) 0
Congenital, familial and genetic disorders			
Developmental hip dysplasia subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	1 / 24 (4.17%) 1	3 / 65 (4.62%) 3
Cryptorchism subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	1 / 24 (4.17%) 1	2 / 65 (3.08%) 2
High arched palate subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	2 / 24 (8.33%) 2	1 / 65 (1.54%) 1
Cardiac disorders			
Bradycardia subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 24 (0.00%) 0	6 / 65 (9.23%) 7
Tachycardia			



subjects affected / exposed	2 / 13 (15.38%)	4 / 24 (16.67%)	5 / 65 (7.69%)
occurrences (all)	2	4	7
Sinus tachycardia			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	1 / 65 (1.54%)
occurrences (all)	0	2	1
Right ventricular hypertrophy			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Right atrial enlargement			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	1	0	1
Pericardial effusion			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
Areflexia			
subjects affected / exposed	2 / 13 (15.38%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	2	0	2
Dizziness			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences (all)	0	1	0
Cognitive disorder			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Disturbance in attention			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Autonomic nervous system imbalance			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences (all)	1	1	0
Dysarthria			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	1	0	1
Migraine			

subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Lethargy			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Intracranial pressure increased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Hyporeflexia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Horner\'s syndrome			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	4 / 13 (30.77%)	3 / 24 (12.50%)	8 / 65 (12.31%)
occurrences (all)	4	3	9
Motor developmental delay			
subjects affected / exposed	3 / 13 (23.08%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences (all)	3	0	2
Paraesthesia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Nystagmus			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	4 / 65 (6.15%)
occurrences (all)	0	0	4
Myoclonus			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Muscle contractions involuntary			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	1	0	1
Blood and lymphatic system disorders			

Thrombocytosis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	0	0	2
Lymphadenopathy			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Leukocytosis			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	3 / 65 (4.62%)
occurrences (all)	1	0	3
Iron deficiency anaemia			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	2 / 65 (3.08%)
occurrences (all)	0	2	2
Anaemia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	6 / 65 (9.23%)
occurrences (all)	1	0	8
Ear and labyrinth disorders			
Cerumen impaction			
subjects affected / exposed	2 / 13 (15.38%)	2 / 24 (8.33%)	0 / 65 (0.00%)
occurrences (all)	2	2	0
Ear pain			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences (all)	1	0	7
Hyperacusis			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Myringosclerosis			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Motion sickness			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Eye disorders			

Amblyopia			
subjects affected / exposed	2 / 13 (15.38%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	2	0	1
Astigmatism			
subjects affected / exposed	1 / 13 (7.69%)	2 / 24 (8.33%)	3 / 65 (4.62%)
occurrences (all)	1	2	3
Chalazion			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	1 / 65 (1.54%)
occurrences (all)	0	3	1
Eyelid cyst			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Hypermetropia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	1	0	1
Strabismus			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	4 / 65 (6.15%)
occurrences (all)	0	1	5
Myopia			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	2 / 65 (3.08%)
occurrences (all)	1	1	2
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	1 / 65 (1.54%)
occurrences (all)	0	1	1
Abdominal distension			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	4 / 65 (6.15%)
occurrences (all)	0	0	6
Abdominal pain			
subjects affected / exposed	2 / 13 (15.38%)	1 / 24 (4.17%)	4 / 65 (6.15%)
occurrences (all)	3	2	5
Colitis ulcerative			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Constipation			

subjects affected / exposed	3 / 13 (23.08%)	7 / 24 (29.17%)	22 / 65 (33.85%)
occurrences (all)	4	14	28
Diarrhoea			
subjects affected / exposed	4 / 13 (30.77%)	8 / 24 (33.33%)	16 / 65 (24.62%)
occurrences (all)	5	11	18
Dyspepsia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal motility disorder			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	2 / 65 (3.08%)
occurrences (all)	1	1	3
Gastritis haemorrhagic			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 13 (0.00%)	5 / 24 (20.83%)	2 / 65 (3.08%)
occurrences (all)	0	6	4
Dysphagia			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	5 / 65 (7.69%)
occurrences (all)	0	2	5
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 13 (0.00%)	4 / 24 (16.67%)	9 / 65 (13.85%)
occurrences (all)	0	4	10
Hiatus hernia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	0	0	1
Ileus paralytic			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Oral pain			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Lip dry			

subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Lip swelling			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	2 / 13 (15.38%)	1 / 24 (4.17%)	6 / 65 (9.23%)
occurrences (all)	6	1	10
Impaired gastric emptying			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences (all)	0	1	0
Saliva discolouration			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences (all)	1	5	0
Salivary hypersecretion			
subjects affected / exposed	1 / 13 (7.69%)	6 / 24 (25.00%)	10 / 65 (15.38%)
occurrences (all)	1	14	17
Scalloped tongue			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Teething			
subjects affected / exposed	0 / 13 (0.00%)	4 / 24 (16.67%)	9 / 65 (13.85%)
occurrences (all)	0	4	10
Toothache			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	1 / 65 (1.54%)
occurrences (all)	0	2	4
Vomiting			
subjects affected / exposed	7 / 13 (53.85%)	9 / 24 (37.50%)	23 / 65 (35.38%)
occurrences (all)	23	21	53
Tooth impacted			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences (all)	0	0	2

Skin and subcutaneous tissue disorders			
Decubitus ulcer			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	3 / 65 (4.62%)
occurrences (all)	0	2	3
Acne			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	1 / 65 (1.54%)
occurrences (all)	1	1	1
Blister			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	0 / 65 (0.00%)
occurrences (all)	0	2	0
Dry skin			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Dermatitis diaper			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	2 / 65 (3.08%)
occurrences (all)	0	2	2
Dermatitis contact			
subjects affected / exposed	0 / 13 (0.00%)	3 / 24 (12.50%)	3 / 65 (4.62%)
occurrences (all)	0	4	4
Dermatitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Ecchymosis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Keratosis pilaris			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	0 / 65 (0.00%)
occurrences (all)	0	2	0
Erythema			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	3 / 65 (4.62%)
occurrences (all)	1	1	3
Eczema			

subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	2 / 65 (3.08%)
occurrences (all)	1	1	2
Miliaria			
subjects affected / exposed	0 / 13 (0.00%)	3 / 24 (12.50%)	2 / 65 (3.08%)
occurrences (all)	0	4	2
Petechiae			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	1	0	1
Photosensitivity reaction			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Pruritus			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Rash			
subjects affected / exposed	1 / 13 (7.69%)	4 / 24 (16.67%)	7 / 65 (10.77%)
occurrences (all)	1	7	8
Scab			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Skin mass			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences (all)	0	1	0
Urticaria			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	2 / 65 (3.08%)
occurrences (all)	0	2	3
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	0	0	1
Pollakiuria			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences (all)	0	1	0
Proteinuria			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	7 / 65 (10.77%)
occurrences (all)	0	2	11



Urinary retention subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	1 / 24 (4.17%) 1	3 / 65 (4.62%) 3
Kidney enlargement subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	0 / 65 (0.00%) 0
Haematuria subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	1 / 24 (4.17%) 1	0 / 65 (0.00%) 0
Dysuria subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	1 / 65 (1.54%) 1
Endocrine disorders Precocious puberty subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	2 / 24 (8.33%) 2	4 / 65 (6.15%) 5
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 2	3 / 24 (12.50%) 3	4 / 65 (6.15%) 5
Deformity thorax subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	0 / 65 (0.00%) 0
Bone pain subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	1 / 65 (1.54%) 1
Back pain subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	2 / 24 (8.33%) 4	7 / 65 (10.77%) 7
Foot deformity subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	1 / 65 (1.54%) 1
Knee deformity subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	0 / 65 (0.00%) 0
Joint range of motion decreased			

subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	2 / 65 (3.08%)
occurrences (all)	0	2	3
Joint laxity			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	0	0	1
Joint contracture			
subjects affected / exposed	4 / 13 (30.77%)	6 / 24 (25.00%)	16 / 65 (24.62%)
occurrences (all)	7	11	26
Hip deformity			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	9 / 65 (13.85%)
occurrences (all)	2	0	17
Kyphoscoliosis			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	5 / 65 (7.69%)
occurrences (all)	0	2	7
Kyphosis			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	10 / 65 (15.38%)
occurrences (all)	1	0	15
Muscle atrophy			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Muscle spasms			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	3 / 65 (4.62%)
occurrences (all)	0	0	3
Muscle contracture			
subjects affected / exposed	5 / 13 (38.46%)	6 / 24 (25.00%)	18 / 65 (27.69%)
occurrences (all)	6	8	44
Musculoskeletal chest pain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Limb asymmetry			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	1	0	1
Pain in extremity			

subjects affected / exposed	1 / 13 (7.69%)	4 / 24 (16.67%)	7 / 65 (10.77%)
occurrences (all)	1	5	10
Pathological fracture			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	0	0	1
Scoliosis			
subjects affected / exposed	6 / 13 (46.15%)	10 / 24 (41.67%)	38 / 65 (58.46%)
occurrences (all)	6	10	60
Spinal deformity			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Neuromuscular scoliosis			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	1 / 65 (1.54%)
occurrences (all)	0	1	2
Osteopenia			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	9 / 65 (13.85%)
occurrences (all)	0	1	10
Osteoporosis			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	7 / 65 (10.77%)
occurrences (all)	1	1	7
Tendinous contracture			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	1 / 65 (1.54%)
occurrences (all)	2	1	2
Infections and infestations			
Abdominal abscess			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Bronchiolitis			
subjects affected / exposed	2 / 13 (15.38%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences (all)	2	0	2
Adenovirus infection			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	0 / 65 (0.00%)
occurrences (all)	0	2	0

Bacterial disease carrier			
subjects affected / exposed	0 / 13 (0.00%)	4 / 24 (16.67%)	4 / 65 (6.15%)
occurrences (all)	0	7	4
Bacterial infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Acute sinusitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Coronavirus infection			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	2 / 65 (3.08%)
occurrences (all)	1	1	3
Covid-19			
subjects affected / exposed	4 / 13 (30.77%)	1 / 24 (4.17%)	16 / 65 (24.62%)
occurrences (all)	4	1	18
Coxsackie viral infection			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences (all)	0	1	0
Conjunctivitis			
subjects affected / exposed	2 / 13 (15.38%)	3 / 24 (12.50%)	8 / 65 (12.31%)
occurrences (all)	2	4	10
Bronchitis			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	10 / 65 (15.38%)
occurrences (all)	1	1	15
Cellulitis			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	2 / 65 (3.08%)
occurrences (all)	0	2	2
Clostridium difficile infection			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Croup infectious			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Cystitis			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences (all)	0	1	0

Ear infection			
subjects affected / exposed	2 / 13 (15.38%)	3 / 24 (12.50%)	21 / 65 (32.31%)
occurrences (all)	2	6	31
Ear infection fungal			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	1 / 65 (1.54%)
occurrences (all)	0	2	1
Enterovirus infection			
subjects affected / exposed	0 / 13 (0.00%)	4 / 24 (16.67%)	4 / 65 (6.15%)
occurrences (all)	0	6	4
Gastroenteritis viral			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	4 / 65 (6.15%)
occurrences (all)	0	1	4
Fungal skin infection			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	2 / 65 (3.08%)
occurrences (all)	0	1	2
Gastritis viral			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	1 / 13 (7.69%)	2 / 24 (8.33%)	9 / 65 (13.85%)
occurrences (all)	1	3	10
Eye infection			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	0 / 65 (0.00%)
occurrences (all)	1	1	0
Gastrointestinal viral infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	0	0	2
Hand-foot-and-mouth disease			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Hordeolum			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	4 / 65 (6.15%)
occurrences (all)	0	2	4
Impetigo			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	0 / 65 (0.00%)
occurrences (all)	0	3	0

Influenza			
subjects affected / exposed	2 / 13 (15.38%)	3 / 24 (12.50%)	13 / 65 (20.00%)
occurrences (all)	4	3	14
Klebsiella infection			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	0 / 65 (0.00%)
occurrences (all)	0	2	0
Lower respiratory tract infection			
subjects affected / exposed	1 / 13 (7.69%)	3 / 24 (12.50%)	4 / 65 (6.15%)
occurrences (all)	1	3	7
Lower respiratory tract infection viral			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Metapneumovirus infection			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	1	0	1
Otitis externa			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	4 / 65 (6.15%)
occurrences (all)	2	0	8
Oral fungal infection			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	1 / 65 (1.54%)
occurrences (all)	0	3	1
Otitis media			
subjects affected / exposed	4 / 13 (30.77%)	4 / 24 (16.67%)	14 / 65 (21.54%)
occurrences (all)	7	7	23
Otitis media acute			
subjects affected / exposed	2 / 13 (15.38%)	2 / 24 (8.33%)	3 / 65 (4.62%)
occurrences (all)	2	2	3
Moraxella infection			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	2 / 65 (3.08%)
occurrences (all)	0	2	2
Mycoplasma infection			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Nasopharyngitis			
subjects affected / exposed	4 / 13 (30.77%)	5 / 24 (20.83%)	26 / 65 (40.00%)
occurrences (all)	14	20	74

Oral candidiasis			
subjects affected / exposed	1 / 13 (7.69%)	3 / 24 (12.50%)	0 / 65 (0.00%)
occurrences (all)	1	3	0
Pneumonia			
subjects affected / exposed	4 / 13 (30.77%)	6 / 24 (25.00%)	18 / 65 (27.69%)
occurrences (all)	9	8	24
Pharyngitis streptococcal			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences (all)	1	0	3
Pseudomonas infection			
subjects affected / exposed	0 / 13 (0.00%)	6 / 24 (25.00%)	11 / 65 (16.92%)
occurrences (all)	0	10	17
Parainfluenzae virus infection			
subjects affected / exposed	2 / 13 (15.38%)	0 / 24 (0.00%)	5 / 65 (7.69%)
occurrences (all)	2	0	5
Pharyngitis			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	4 / 65 (6.15%)
occurrences (all)	0	2	4
Pneumonia bacterial			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	0	0	1
Postoperative wound infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	0	0	1
Respiratory syncytial virus infection			
subjects affected / exposed	2 / 13 (15.38%)	2 / 24 (8.33%)	8 / 65 (12.31%)
occurrences (all)	3	2	10
Pneumonia aspiration			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	7 / 65 (10.77%)
occurrences (all)	0	2	8
Respiratory tract infection			
subjects affected / exposed	4 / 13 (30.77%)	2 / 24 (8.33%)	22 / 65 (33.85%)
occurrences (all)	16	4	44
Respiratory tract infection viral			
subjects affected / exposed	2 / 13 (15.38%)	1 / 24 (4.17%)	6 / 65 (9.23%)
occurrences (all)	3	1	7

Rhinitis			
subjects affected / exposed	0 / 13 (0.00%)	6 / 24 (25.00%)	5 / 65 (7.69%)
occurrences (all)	0	7	17
Rhinovirus infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	12 / 65 (18.46%)
occurrences (all)	0	0	20
Serratia infection			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	0 / 65 (0.00%)
occurrences (all)	0	2	0
Sinusitis			
subjects affected / exposed	1 / 13 (7.69%)	2 / 24 (8.33%)	6 / 65 (9.23%)
occurrences (all)	1	2	6
Staphylococcal infection			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	7 / 65 (10.77%)
occurrences (all)	0	1	11
Stenotrophomonas infection			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	1 / 65 (1.54%)
occurrences (all)	0	2	1
Respiratory tract infection bacterial			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	1	0	0
Stoma site infection			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	4 / 65 (6.15%)
occurrences (all)	1	2	5
Suspected covid-19			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Tonsillitis			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	1 / 65 (1.54%)
occurrences (all)	1	1	2
Tooth abscess			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0
Stoma site cellulitis			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	2 / 65 (3.08%)
occurrences (all)	0	6	2



Upper respiratory tract infection subjects affected / exposed occurrences (all)	11 / 13 (84.62%) 16	14 / 24 (58.33%) 35	34 / 65 (52.31%) 109
Upper respiratory tract infection bacterial subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	1 / 65 (1.54%) 1
Urinary tract infection subjects affected / exposed occurrences (all)	3 / 13 (23.08%) 5	3 / 24 (12.50%) 7	10 / 65 (15.38%) 20
Tracheitis subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	4 / 24 (16.67%) 5	3 / 65 (4.62%) 8
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 3	1 / 24 (4.17%) 1	5 / 65 (7.69%) 14
Viral infection subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 2	1 / 24 (4.17%) 1	3 / 65 (4.62%) 3
Metabolism and nutrition disorders			
Feeding intolerance subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	1 / 24 (4.17%) 1	0 / 65 (0.00%) 0
Electrolyte imbalance subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	1 / 65 (1.54%) 1
Dehydration subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	2 / 24 (8.33%) 3	6 / 65 (9.23%) 7
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	2 / 24 (8.33%) 3	0 / 65 (0.00%) 0
Hyponatraemia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 24 (0.00%) 0	1 / 65 (1.54%) 1
Hypokalaemia			

subjects affected / exposed	1 / 13 (7.69%)	3 / 24 (12.50%)	10 / 65 (15.38%)
occurrences (all)	1	5	11
Hypoglycaemia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	3 / 65 (4.62%)
occurrences (all)	1	0	4
Hypochloraemia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	0	0	1
Malnutrition			
subjects affected / exposed	1 / 13 (7.69%)	0 / 24 (0.00%)	6 / 65 (9.23%)
occurrences (all)	1	0	6
Iron deficiency			
subjects affected / exposed	0 / 13 (0.00%)	2 / 24 (8.33%)	2 / 65 (3.08%)
occurrences (all)	0	2	2
Hypovolaemia			
subjects affected / exposed	0 / 13 (0.00%)	1 / 24 (4.17%)	1 / 65 (1.54%)
occurrences (all)	0	1	1
Metabolic acidosis			
subjects affected / exposed	2 / 13 (15.38%)	1 / 24 (4.17%)	2 / 65 (3.08%)
occurrences (all)	2	1	2
Obesity			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	1 / 65 (1.54%)
occurrences (all)	0	0	1
Vitamin d deficiency			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	2 / 65 (3.08%)
occurrences (all)	0	0	2
Weight gain poor			
subjects affected / exposed	1 / 13 (7.69%)	1 / 24 (4.17%)	3 / 65 (4.62%)
occurrences (all)	1	2	3
Metabolic alkalosis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 24 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Infantile SMA Onset 232SM202	Later SMA Onset 232SM202	Later SMA Onset CS12 Type 3
Total subjects affected by non-serious adverse events			
subjects affected / exposed	12 / 12 (100.00%)	8 / 8 (100.00%)	25 / 25 (100.00%)

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Skin papilloma			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	2 / 25 (8.00%)
occurrences (all)	0	0	2
Hair follicle tumour benign			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	2 / 12 (16.67%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	3	0	0
Hypotension			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	3 / 12 (25.00%)	0 / 8 (0.00%)	3 / 25 (12.00%)
occurrences (all)	3	0	4
Developmental delay			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Gait disturbance			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	3 / 25 (12.00%)
occurrences (all)	0	0	3
Infusion site bruising			
subjects affected / exposed	0 / 12 (0.00%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
Medical device site haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	2 / 25 (8.00%)
occurrences (all)	0	0	2

Pneumatosis subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	5 / 12 (41.67%) 15	5 / 8 (62.50%) 6	3 / 25 (12.00%) 5
Pain subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 8 (12.50%) 1	0 / 25 (0.00%) 0
Immune system disorders Drug hypersensitivity subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Multiple allergies subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 8 (12.50%) 2	0 / 25 (0.00%) 0
Seasonal allergy subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	2 / 25 (8.00%) 2
Reproductive system and breast disorders Heavy menstrual bleeding subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	1 / 25 (4.00%) 1
Testicular atrophy subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Acute respiratory failure subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Adenoidal hypertrophy subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Aspiration subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0

Asthma			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	1
Atelectasis			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Bronchial wall thickening			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Chronic respiratory failure			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Epiglottic oedema			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Emphysema			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	2 / 12 (16.67%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	3	0	0
Cough			
subjects affected / exposed	5 / 12 (41.67%)	5 / 8 (62.50%)	2 / 25 (8.00%)
occurrences (all)	7	8	3
Epistaxis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	3 / 25 (12.00%)
occurrences (all)	0	0	4
Increased upper airway secretion			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Increased viscosity of upper respiratory secretion			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Increased bronchial secretion			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Laryngospasm			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract congestion			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	2 / 12 (16.67%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	4	0	0
Lung infiltration			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			
subjects affected / exposed	3 / 12 (25.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	3	0	0
Obstructive sleep apnoea syndrome			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Obstructive airways disorder			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Noninfective bronchitis			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Oropharyngeal pain			
subjects affected / exposed	1 / 12 (8.33%)	1 / 8 (12.50%)	3 / 25 (12.00%)
occurrences (all)	2	1	3
Respiratory disorder			
subjects affected / exposed	1 / 12 (8.33%)	1 / 8 (12.50%)	1 / 25 (4.00%)
occurrences (all)	1	1	1
Rales			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Pulmonary oedema			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Productive cough			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Respiratory distress			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Rhinorrhoea			
subjects affected / exposed	1 / 12 (8.33%)	2 / 8 (25.00%)	1 / 25 (4.00%)
occurrences (all)	1	2	1
Rhinitis allergic			
subjects affected / exposed	0 / 12 (0.00%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
Restrictive pulmonary disease			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Tonsillar hypertrophy			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	1
Tachypnoea			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Sputum discoloured			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Sleep apnoea syndrome			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			

Anxiety			
subjects affected / exposed	2 / 12 (16.67%)	0 / 8 (0.00%)	3 / 25 (12.00%)
occurrences (all)	2	0	3
Agitation			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Anxiety disorder			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Attention deficit hyperactivity disorder			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	1
Panic attack			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	2 / 25 (8.00%)
occurrences (all)	0	0	2
Mental status changes			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Learning disability			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Irritability			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Encopresis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
Depression			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	2 / 25 (8.00%)
occurrences (all)	0	0	2
Product issues			



Device malfunction subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Device dislocation subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Investigations			
Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Blood albumin decreased subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Blood iron decreased subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Blood potassium decreased subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Bone density decreased subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Breath sounds abnormal subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Cardiac murmur subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Clostridium test positive subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Heart rate increased subjects affected / exposed occurrences (all)	3 / 12 (25.00%) 5	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Electrocardiogram qt prolonged			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Haemoglobin decreased			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Crystal urine present			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Oxygen consumption decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Occult blood positive			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Mean platelet volume decreased			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Oxygen saturation decreased			
subjects affected / exposed	2 / 12 (16.67%)	0 / 8 (0.00%)	1 / 25 (4.00%)
occurrences (all)	3	0	1
Qrs axis abnormal			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Pseudomonas test positive			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Prothrombin time prolonged			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Platelet count increased			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0

Red blood cell count increased subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Red blood cell sedimentation rate increased subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Sars-cov-2 test positive subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	1 / 25 (4.00%) 1
Vitamin d decreased subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	1 / 25 (4.00%) 1
White blood cells urine positive subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Weight increased subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Weight decreased subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	1 / 25 (4.00%) 1
Von willebrand\'s factor activity decreased subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
White blood cell count increased subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Arthropod bite subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Concussion			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	2 / 25 (8.00%)
occurrences (all)	0	0	2
Anaesthetic complication neurological			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Anaesthetic complication			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	1
Accident			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Femur fracture			
subjects affected / exposed	1 / 12 (8.33%)	2 / 8 (25.00%)	0 / 25 (0.00%)
occurrences (all)	2	3	0
Fibula fracture			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal stoma complication			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Humerus fracture			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	6 / 25 (24.00%)
occurrences (all)	0	0	10
Incision site swelling			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Endotracheal intubation complication			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Extraskkeletal ossification			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0

Immunisation reaction			
subjects affected / exposed	0 / 12 (0.00%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
Post procedural contusion			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Post procedural constipation			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Post procedural complication			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Post lumbar puncture syndrome			
subjects affected / exposed	0 / 12 (0.00%)	2 / 8 (25.00%)	15 / 25 (60.00%)
occurrences (all)	0	2	34
Palate injury			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Lower limb fracture			
subjects affected / exposed	1 / 12 (8.33%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences (all)	1	1	0
Post procedural haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	1
Ligament sprain			
subjects affected / exposed	1 / 12 (8.33%)	1 / 8 (12.50%)	5 / 25 (20.00%)
occurrences (all)	1	1	5
Joint dislocation			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Post procedural inflammation			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Procedural hypotension			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0

Procedural pain			
subjects affected / exposed	2 / 12 (16.67%)	2 / 8 (25.00%)	11 / 25 (44.00%)
occurrences (all)	2	4	34
Procedural pneumothorax			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Procedural vomiting			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Respiratory tract procedural complication			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Skin abrasion			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Stoma site discharge			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Stoma site erythema			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Stoma site haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Stoma site hypergranulation			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Suture rupture			
subjects affected / exposed	0 / 12 (0.00%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
Tibia fracture			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Tooth fracture			

subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Wound dehiscence subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Wound secretion subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Congenital, familial and genetic disorders			
Developmental hip dysplasia subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	1 / 8 (12.50%) 1	0 / 25 (0.00%) 0
Cryptorchism subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
High arched palate subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Cardiac disorders			
Bradycardia subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Right ventricular hypertrophy subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Right atrial enlargement subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Pericardial effusion			

subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Nervous system disorders			
Areflexia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	2 / 25 (8.00%)
occurrences (all)	0	0	2
Cognitive disorder			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Disturbance in attention			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Autonomic nervous system imbalance			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Dysarthria			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Migraine			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	2 / 25 (8.00%)
occurrences (all)	0	0	2
Lethargy			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	2	0	0
Intracranial pressure increased			
subjects affected / exposed	1 / 12 (8.33%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences (all)	1	1	0
Hyporeflexia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Horner\'s syndrome			



subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Headache			
subjects affected / exposed	1 / 12 (8.33%)	3 / 8 (37.50%)	17 / 25 (68.00%)
occurrences (all)	1	5	47
Motor developmental delay			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 12 (0.00%)	1 / 8 (12.50%)	1 / 25 (4.00%)
occurrences (all)	0	1	1
Nystagmus			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Myoclonus			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Muscle contractions involuntary			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	1 / 25 (4.00%)
occurrences (all)	1	0	1
Tremor			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	2
Blood and lymphatic system disorders			
Thrombocytosis			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Thrombocytopenia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Lymphadenopathy			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Leukocytosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0

Iron deficiency anaemia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Anaemia subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	1 / 8 (12.50%) 1	0 / 25 (0.00%) 0
Ear and labyrinth disorders			
Cerumen impaction subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Ear pain subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	2 / 25 (8.00%) 2
Hyperacusis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Myringosclerosis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Motion sickness subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 8 (12.50%) 1	0 / 25 (0.00%) 0
Eye disorders			
Amblyopia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Astigmatism subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 8 (12.50%) 1	1 / 25 (4.00%) 1
Chalazion subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Eyelid cyst subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Hypermetropia			

subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Strabismus			
subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Myopia			
subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Abdominal distension			
subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Abdominal pain			
subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	1 / 25 (4.00%) 1
Colitis ulcerative			
subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 3	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Constipation			
subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 3	3 / 8 (37.50%) 3	1 / 25 (4.00%) 1
Diarrhoea			
subjects affected / exposed occurrences (all)	2 / 12 (16.67%) 3	2 / 8 (25.00%) 2	0 / 25 (0.00%) 0
Dyspepsia			
subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	1 / 25 (4.00%) 1
Gastrointestinal motility disorder			
subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Gastritis			
subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	1 / 25 (4.00%) 1

Gastritis haemorrhagic subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Gastrointestinal haemorrhage subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Dysphagia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Gastrooesophageal reflux disease subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Hiatus hernia subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 3	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Ileus paralytic subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Oral pain subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Lip dry subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Lip swelling subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Nausea subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	2 / 25 (8.00%) 3
Impaired gastric emptying subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Saliva discolouration subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0

Salivary hypersecretion subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Scalloped tongue subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Teething subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Toothache subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Vomiting subjects affected / exposed occurrences (all)	3 / 12 (25.00%) 6	4 / 8 (50.00%) 5	4 / 25 (16.00%) 15
Tooth impacted subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Hepatobiliary disorders Hepatic steatosis subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Skin and subcutaneous tissue disorders Decubitus ulcer subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Acne subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	3 / 25 (12.00%) 4
Alopecia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Blister subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Dry skin			

subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Dermatitis diaper			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Dermatitis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
Ecchymosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Keratosis pilaris			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Miliaria			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Photosensitivity reaction			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	1
Rash			

subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Scab			
subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Skin mass			
subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Urticaria			
subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Pollakiuria			
subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Proteinuria			
subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	2 / 25 (8.00%) 2
Urinary retention			
subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Kidney enlargement			
subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Haematuria			
subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Dysuria			
subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 8 (12.50%) 1	0 / 25 (0.00%) 0
Endocrine disorders			
Precocious puberty			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	2 / 12 (16.67%)	0 / 8 (0.00%)	3 / 25 (12.00%)
occurrences (all)	2	0	3
Deformity thorax			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Bone pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	2 / 12 (16.67%)	1 / 8 (12.50%)	11 / 25 (44.00%)
occurrences (all)	2	1	15
Foot deformity			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	1 / 25 (4.00%)
occurrences (all)	1	0	1
Knee deformity			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Joint range of motion decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Joint laxity			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Joint contracture			
subjects affected / exposed	2 / 12 (16.67%)	1 / 8 (12.50%)	3 / 25 (12.00%)
occurrences (all)	2	1	3
Hip deformity			
subjects affected / exposed	0 / 12 (0.00%)	2 / 8 (25.00%)	0 / 25 (0.00%)
occurrences (all)	0	4	0
Kyphoscoliosis			



subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Kyphosis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 8 (12.50%)	1 / 25 (4.00%)
occurrences (all)	0	1	1
Muscle atrophy			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Muscle contracture			
subjects affected / exposed	2 / 12 (16.67%)	1 / 8 (12.50%)	1 / 25 (4.00%)
occurrences (all)	2	1	2
Musculoskeletal chest pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	1
Limb asymmetry			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	1 / 12 (8.33%)	1 / 8 (12.50%)	6 / 25 (24.00%)
occurrences (all)	2	1	11
Pathological fracture			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Scoliosis			
subjects affected / exposed	3 / 12 (25.00%)	5 / 8 (62.50%)	2 / 25 (8.00%)
occurrences (all)	3	8	2
Spinal deformity			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Neck pain			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Neuromuscular scoliosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Osteopenia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Osteoporosis			
subjects affected / exposed	0 / 12 (0.00%)	2 / 8 (25.00%)	0 / 25 (0.00%)
occurrences (all)	0	2	0
Tendinous contracture			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Abdominal abscess			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Bronchiolitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Adenovirus infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Bacterial disease carrier			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Bacterial infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Acute sinusitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Coronavirus infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0

Covid-19			
subjects affected / exposed	5 / 12 (41.67%)	2 / 8 (25.00%)	5 / 25 (20.00%)
occurrences (all)	6	3	6
Coxsackie viral infection			
subjects affected / exposed	0 / 12 (0.00%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
Conjunctivitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	2 / 12 (16.67%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences (all)	2	1	0
Cellulitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Clostridium difficile infection			
subjects affected / exposed	2 / 12 (16.67%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	2	0	0
Croup infectious			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Ear infection			
subjects affected / exposed	2 / 12 (16.67%)	1 / 8 (12.50%)	1 / 25 (4.00%)
occurrences (all)	2	1	1
Ear infection fungal			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Enterovirus infection			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis viral			
subjects affected / exposed	1 / 12 (8.33%)	1 / 8 (12.50%)	5 / 25 (20.00%)
occurrences (all)	1	1	5

Fungal skin infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Gastritis viral			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	2 / 12 (16.67%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences (all)	2	3	0
Eye infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal viral infection			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Hand-foot-and-mouth disease			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Impetigo			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	0 / 12 (0.00%)	1 / 8 (12.50%)	3 / 25 (12.00%)
occurrences (all)	0	1	4
Klebsiella infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 12 (0.00%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
Lower respiratory tract infection viral			
subjects affected / exposed	0 / 12 (0.00%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences (all)	0	1	0

Metapneumovirus infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Otitis externa			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Oral fungal infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	1 / 12 (8.33%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences (all)	1	1	0
Otitis media acute			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Moraxella infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Mycoplasma infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	4 / 12 (33.33%)	1 / 8 (12.50%)	8 / 25 (32.00%)
occurrences (all)	5	1	10
Oral candidiasis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	4 / 12 (33.33%)	1 / 8 (12.50%)	0 / 25 (0.00%)
occurrences (all)	5	3	0
Pharyngitis streptococcal			
subjects affected / exposed	0 / 12 (0.00%)	1 / 8 (12.50%)	3 / 25 (12.00%)
occurrences (all)	0	1	3
Pseudomonas infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0

Parainfluenzae virus infection subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Pharyngitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Pneumonia bacterial subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Postoperative wound infection subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Respiratory syncytial virus infection subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 8 (12.50%) 1	0 / 25 (0.00%) 0
Pneumonia aspiration subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Respiratory tract infection subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	2 / 8 (25.00%) 3	0 / 25 (0.00%) 0
Respiratory tract infection viral subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	2 / 8 (25.00%) 4	0 / 25 (0.00%) 0
Rhinitis subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Rhinovirus infection subjects affected / exposed occurrences (all)	2 / 12 (16.67%) 2	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Serratia infection subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Sinusitis subjects affected / exposed occurrences (all)	2 / 12 (16.67%) 2	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0

Staphylococcal infection			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	3	0	0
Stenotrophomonas infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection bacterial			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Stoma site infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Suspected covid-19			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Tonsillitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	1
Tooth abscess			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Stoma site cellulitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	3 / 12 (25.00%)	6 / 8 (75.00%)	5 / 25 (20.00%)
occurrences (all)	6	18	10
Upper respiratory tract infection bacterial			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Urinary tract infection			
subjects affected / exposed	1 / 12 (8.33%)	1 / 8 (12.50%)	1 / 25 (4.00%)
occurrences (all)	2	1	3
Tracheitis			

subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	2 / 25 (8.00%)
occurrences (all)	0	0	2
Viral infection			
subjects affected / exposed	0 / 12 (0.00%)	1 / 8 (12.50%)	4 / 25 (16.00%)
occurrences (all)	0	2	5
Metabolism and nutrition disorders			
Feeding intolerance			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Electrolyte imbalance			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Dehydration			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	1 / 25 (4.00%)
occurrences (all)	2	0	1
Hypocalcaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Hypokalaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Hypoglycaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Hypochloraemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Malnutrition			
subjects affected / exposed	0 / 12 (0.00%)	0 / 8 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0



Iron deficiency subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Hypovolaemia subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Metabolic acidosis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Obesity subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	2 / 25 (8.00%) 2
Vitamin d deficiency subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 8 (12.50%) 1	0 / 25 (0.00%) 0
Weight gain poor subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0
Metabolic alkalosis subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0	0 / 25 (0.00%) 0

<b>Non-serious adverse events</b>	Later SMA Onset CS12 Type 2	Later SMA Onset CS4 Previous Control	Later SMA Onset CS4 Previous ISIS 396443
Total subjects affected by non-serious adverse events subjects affected / exposed	20 / 20 (100.00%)	40 / 42 (95.24%)	79 / 83 (95.18%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin papilloma subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 42 (2.38%) 1	1 / 83 (1.20%) 1
Hair follicle tumour benign subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	1 / 83 (1.20%) 2
Vascular disorders Hypertension subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0

Hypotension subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 42 (2.38%) 1	1 / 83 (1.20%) 1
General disorders and administration site conditions			
Fatigue subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	1 / 83 (1.20%) 1
Developmental delay subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Gait disturbance subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Infusion site bruising subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Medical device site haemorrhage subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Non-cardiac chest pain subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Peripheral swelling subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 42 (2.38%) 1	2 / 83 (2.41%) 2
Pneumatosis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	10 / 20 (50.00%) 21	21 / 42 (50.00%) 55	39 / 83 (46.99%) 117
Pain subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 42 (2.38%) 1	2 / 83 (2.41%) 2
Immune system disorders			

Drug hypersensitivity subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 42 (2.38%) 1	2 / 83 (2.41%) 2
Multiple allergies subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	1 / 83 (1.20%) 1
Seasonal allergy subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	3 / 42 (7.14%) 3	5 / 83 (6.02%) 6
Reproductive system and breast disorders Heavy menstrual bleeding subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Testicular atrophy subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Acute respiratory failure subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	1 / 83 (1.20%) 2
Adenoidal hypertrophy subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 42 (0.00%) 0	1 / 83 (1.20%) 1
Aspiration subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Asthma subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	3 / 42 (7.14%) 3	0 / 83 (0.00%) 0
Atelectasis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	2 / 83 (2.41%) 3
Bronchial wall thickening subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Chronic respiratory failure			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Epiglottic oedema			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Emphysema			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1
Cough			
subjects affected / exposed	6 / 20 (30.00%)	15 / 42 (35.71%)	29 / 83 (34.94%)
occurrences (all)	7	33	62
Epistaxis			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	2 / 83 (2.41%)
occurrences (all)	0	1	3
Increased upper airway secretion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1
Increased viscosity of upper respiratory secretion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Increased bronchial secretion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1
Hypoxia			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	2 / 83 (2.41%)
occurrences (all)	1	0	2
Laryngospasm			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	1	0	1
Lower respiratory tract congestion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1

Nasal congestion			
subjects affected / exposed	1 / 20 (5.00%)	1 / 42 (2.38%)	9 / 83 (10.84%)
occurrences (all)	1	3	12
Lung infiltration			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1
Pleural effusion			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	1 / 83 (1.20%)
occurrences (all)	0	1	1
Obstructive sleep apnoea syndrome			
subjects affected / exposed	2 / 20 (10.00%)	4 / 42 (9.52%)	5 / 83 (6.02%)
occurrences (all)	2	5	5
Obstructive airways disorder			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Noninfective bronchitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	4 / 20 (20.00%)	8 / 42 (19.05%)	12 / 83 (14.46%)
occurrences (all)	5	9	27
Respiratory disorder			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	2
Rales			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Pulmonary oedema			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences (all)	0	1	0
Productive cough			
subjects affected / exposed	1 / 20 (5.00%)	2 / 42 (4.76%)	5 / 83 (6.02%)
occurrences (all)	1	3	8
Respiratory distress			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1

Rhinorrhoea			
subjects affected / exposed	1 / 20 (5.00%)	4 / 42 (9.52%)	8 / 83 (9.64%)
occurrences (all)	1	7	13
Rhinitis allergic			
subjects affected / exposed	0 / 20 (0.00%)	3 / 42 (7.14%)	0 / 83 (0.00%)
occurrences (all)	0	4	0
Restrictive pulmonary disease			
subjects affected / exposed	1 / 20 (5.00%)	1 / 42 (2.38%)	2 / 83 (2.41%)
occurrences (all)	1	1	2
Tonsillar hypertrophy			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	3 / 83 (3.61%)
occurrences (all)	0	1	3
Tachypnoea			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Sputum discoloured			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Sleep apnoea syndrome			
subjects affected / exposed	0 / 20 (0.00%)	3 / 42 (7.14%)	1 / 83 (1.20%)
occurrences (all)	0	3	1
Wheezing			
subjects affected / exposed	0 / 20 (0.00%)	2 / 42 (4.76%)	1 / 83 (1.20%)
occurrences (all)	0	2	1
Psychiatric disorders			
Anxiety			
subjects affected / exposed	3 / 20 (15.00%)	1 / 42 (2.38%)	4 / 83 (4.82%)
occurrences (all)	3	3	4
Agitation			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences (all)	0	1	0
Anxiety disorder			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Attention deficit hyperactivity disorder			

subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	1 / 83 (1.20%)
occurrences (all)	0	1	1
Panic attack			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Mental status changes			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Learning disability			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Irritability			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1
Insomnia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences (all)	0	1	0
Encopresis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Product issues			
Device malfunction			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Device dislocation			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	2	0	0
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	2 / 83 (2.41%)
occurrences (all)	0	0	2
Blood albumin decreased			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Blood iron decreased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Blood potassium decreased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Bone density decreased			
subjects affected / exposed	1 / 20 (5.00%)	3 / 42 (7.14%)	1 / 83 (1.20%)
occurrences (all)	1	3	1
Breath sounds abnormal			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1
Cardiac murmur			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences (all)	0	1	0
Clostridium test positive			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Heart rate increased			
subjects affected / exposed	0 / 20 (0.00%)	2 / 42 (4.76%)	0 / 83 (0.00%)
occurrences (all)	0	2	0
Electrocardiogram qt prolonged			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Haemoglobin decreased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Crystal urine present			
subjects affected / exposed	0 / 20 (0.00%)	4 / 42 (9.52%)	6 / 83 (7.23%)
occurrences (all)	0	4	7



Oxygen consumption decreased subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Occult blood positive subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Mean platelet volume decreased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Oxygen saturation decreased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	2 / 42 (4.76%) 2	3 / 83 (3.61%) 3
Qrs axis abnormal subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Pseudomonas test positive subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Prothrombin time prolonged subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Platelet count increased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Red blood cell count increased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Red blood cell sedimentation rate increased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Sars-cov-2 test positive subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 42 (2.38%) 1	1 / 83 (1.20%) 1
Vitamin d decreased			

subjects affected / exposed	1 / 20 (5.00%)	1 / 42 (2.38%)	1 / 83 (1.20%)
occurrences (all)	1	1	1
White blood cells urine positive			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1
Weight increased			
subjects affected / exposed	0 / 20 (0.00%)	5 / 42 (11.90%)	0 / 83 (0.00%)
occurrences (all)	0	6	0
Weight decreased			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	3 / 83 (3.61%)
occurrences (all)	0	1	3
Von willebrand\'s factor activity decreased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
White blood cell count increased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 20 (0.00%)	2 / 42 (4.76%)	6 / 83 (7.23%)
occurrences (all)	0	2	6
Arthropod bite			
subjects affected / exposed	0 / 20 (0.00%)	2 / 42 (4.76%)	3 / 83 (3.61%)
occurrences (all)	0	2	3
Concussion			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	1	0	1
Anaesthetic complication neurological			
subjects affected / exposed	1 / 20 (5.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences (all)	1	1	0
Anaesthetic complication			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	1	0	1
Accident			

subjects affected / exposed	1 / 20 (5.00%)	2 / 42 (4.76%)	1 / 83 (1.20%)
occurrences (all)	1	2	1
Femur fracture			
subjects affected / exposed	1 / 20 (5.00%)	5 / 42 (11.90%)	8 / 83 (9.64%)
occurrences (all)	1	5	8
Fibula fracture			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal stoma complication			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Humerus fracture			
subjects affected / exposed	0 / 20 (0.00%)	2 / 42 (4.76%)	3 / 83 (3.61%)
occurrences (all)	0	2	3
Fall			
subjects affected / exposed	3 / 20 (15.00%)	9 / 42 (21.43%)	19 / 83 (22.89%)
occurrences (all)	3	14	23
Incision site swelling			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Endotracheal intubation complication			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	3	0	0
Extraskkeletal ossification			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Immunisation reaction			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1
Post procedural contusion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Post procedural constipation			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Post procedural complication			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	2 / 83 (2.41%)
occurrences (all)	0	0	2
Post lumbar puncture syndrome			
subjects affected / exposed	13 / 20 (65.00%)	7 / 42 (16.67%)	21 / 83 (25.30%)
occurrences (all)	21	18	34
Palate injury			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Lower limb fracture			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	1	0	0
Post procedural haemorrhage			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences (all)	0	1	0
Ligament sprain			
subjects affected / exposed	1 / 20 (5.00%)	1 / 42 (2.38%)	4 / 83 (4.82%)
occurrences (all)	1	1	4
Joint dislocation			
subjects affected / exposed	2 / 20 (10.00%)	3 / 42 (7.14%)	3 / 83 (3.61%)
occurrences (all)	2	3	3
Post procedural inflammation			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Procedural hypotension			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1
Procedural pain			
subjects affected / exposed	6 / 20 (30.00%)	19 / 42 (45.24%)	29 / 83 (34.94%)
occurrences (all)	12	32	55
Procedural pneumothorax			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	1	0	0
Procedural vomiting			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	3 / 83 (3.61%)
occurrences (all)	0	1	3
Respiratory tract procedural			

complication			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	1 / 83 (1.20%)
occurrences (all)	0	1	1
Skin abrasion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1
Stoma site discharge			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Stoma site erythema			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Stoma site haemorrhage			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Stoma site hypergranulation			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Suture rupture			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Tibia fracture			
subjects affected / exposed	1 / 20 (5.00%)	2 / 42 (4.76%)	4 / 83 (4.82%)
occurrences (all)	1	2	4
Tooth fracture			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	3 / 83 (3.61%)
occurrences (all)	1	0	3
Wound dehiscence			
subjects affected / exposed	2 / 20 (10.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	2	0	0
Wound secretion			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	1	0	0
Congenital, familial and genetic disorders			

Developmental hip dysplasia subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 42 (2.38%) 3	5 / 83 (6.02%) 5
Cryptorchism subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
High arched palate subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Cardiac disorders			
Bradycardia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 42 (2.38%) 1	0 / 83 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 42 (2.38%) 1	2 / 83 (2.41%) 2
Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 42 (2.38%) 1	0 / 83 (0.00%) 0
Right ventricular hypertrophy subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Right atrial enlargement subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Pericardial effusion subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Nervous system disorders			
Areflexia subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 42 (2.38%) 1	1 / 83 (1.20%) 1
Dizziness subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 42 (2.38%) 1	2 / 83 (2.41%) 2
Cognitive disorder			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Disturbance in attention			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Autonomic nervous system imbalance			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Dysarthria			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Migraine			
subjects affected / exposed	0 / 20 (0.00%)	2 / 42 (4.76%)	1 / 83 (1.20%)
occurrences (all)	0	2	1
Lethargy			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	1 / 83 (1.20%)
occurrences (all)	0	1	1
Intracranial pressure increased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Hyporeflexia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Horner\'s syndrome			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	5 / 20 (25.00%)	20 / 42 (47.62%)	24 / 83 (28.92%)
occurrences (all)	14	38	53
Motor developmental delay			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	1	0	1
Paraesthesia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1

Nystagmus subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Myoclonus subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Muscle contractions involuntary subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2	1 / 42 (2.38%) 1	4 / 83 (4.82%) 4
Tremor subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 42 (2.38%) 1	3 / 83 (3.61%) 3
Blood and lymphatic system disorders			
Thrombocytosis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Thrombocytopenia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Lymphadenopathy subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Leukocytosis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 42 (2.38%) 1	2 / 83 (2.41%) 2
Iron deficiency anaemia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 42 (2.38%) 1	0 / 83 (0.00%) 0
Anaemia subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 4	1 / 42 (2.38%) 1	1 / 83 (1.20%) 1
Ear and labyrinth disorders			
Cerumen impaction subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	1 / 83 (1.20%) 1
Ear pain			



subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	4 / 83 (4.82%)
occurrences (all)	0	0	5
Hyperacusis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Myringosclerosis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Motion sickness			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	1 / 83 (1.20%)
occurrences (all)	0	1	1
Eye disorders			
Amblyopia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Astigmatism			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1
Chalazion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Eyelid cyst			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Hypermetropia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Strabismus			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Myopia			
subjects affected / exposed	0 / 20 (0.00%)	3 / 42 (7.14%)	4 / 83 (4.82%)
occurrences (all)	0	3	4
Gastrointestinal disorders			
Abdominal pain upper			

subjects affected / exposed	0 / 20 (0.00%)	3 / 42 (7.14%)	5 / 83 (6.02%)
occurrences (all)	0	4	7
Abdominal distension			
subjects affected / exposed	0 / 20 (0.00%)	2 / 42 (4.76%)	2 / 83 (2.41%)
occurrences (all)	0	4	2
Abdominal pain			
subjects affected / exposed	0 / 20 (0.00%)	3 / 42 (7.14%)	7 / 83 (8.43%)
occurrences (all)	0	3	7
Colitis ulcerative			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	1 / 20 (5.00%)	9 / 42 (21.43%)	11 / 83 (13.25%)
occurrences (all)	1	10	11
Diarrhoea			
subjects affected / exposed	1 / 20 (5.00%)	6 / 42 (14.29%)	11 / 83 (13.25%)
occurrences (all)	1	6	13
Dyspepsia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1
Gastrointestinal motility disorder			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	1	0	0
Gastritis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	2 / 83 (2.41%)
occurrences (all)	0	0	2
Gastritis haemorrhagic			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Dysphagia			
subjects affected / exposed	1 / 20 (5.00%)	2 / 42 (4.76%)	0 / 83 (0.00%)
occurrences (all)	1	3	0
Gastrooesophageal reflux disease			

subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	1	0	1
Hiatus hernia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Ileus paralytic			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Lip dry			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Lip swelling			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	2 / 20 (10.00%)	8 / 42 (19.05%)	15 / 83 (18.07%)
occurrences (all)	2	11	18
Impaired gastric emptying			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Saliva discolouration			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Salivary hypersecretion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1
Scalloped tongue			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Teething			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Toothache			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	1 / 83 (1.20%) 1
Vomiting subjects affected / exposed occurrences (all)	7 / 20 (35.00%) 18	18 / 42 (42.86%) 35	35 / 83 (42.17%) 64
Tooth impacted subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Hepatobiliary disorders Hepatic steatosis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Skin and subcutaneous tissue disorders Decubitus ulcer subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	1 / 83 (1.20%) 1
Acne subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	2 / 83 (2.41%) 2
Alopecia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Blister subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 42 (2.38%) 1	0 / 83 (0.00%) 0
Dry skin subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Dermatitis diaper subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Dermatitis contact subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 42 (0.00%) 0	4 / 83 (4.82%) 4
Dermatitis			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Ecchymosis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	2 / 83 (2.41%)
occurrences (all)	1	0	2
Keratosis pilaris			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 20 (0.00%)	4 / 42 (9.52%)	2 / 83 (2.41%)
occurrences (all)	0	6	2
Miliaria			
subjects affected / exposed	1 / 20 (5.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences (all)	1	1	0
Petechiae			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Photosensitivity reaction			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	3 / 83 (3.61%)
occurrences (all)	0	0	5
Rash			
subjects affected / exposed	2 / 20 (10.00%)	6 / 42 (14.29%)	8 / 83 (9.64%)
occurrences (all)	2	7	10
Scab			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	1	0	0
Skin mass			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	1	0	0
Urticaria			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	3 / 42 (7.14%) 3	6 / 83 (7.23%) 9
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	2 / 83 (2.41%)
occurrences (all)	0	0	2
Pollakiuria			
subjects affected / exposed	1 / 20 (5.00%)	1 / 42 (2.38%)	3 / 83 (3.61%)
occurrences (all)	1	2	4
Proteinuria			
subjects affected / exposed	0 / 20 (0.00%)	2 / 42 (4.76%)	8 / 83 (9.64%)
occurrences (all)	0	4	14
Urinary retention			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1
Kidney enlargement			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	2 / 83 (2.41%)
occurrences (all)	0	0	4
Dysuria			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences (all)	0	1	0
Endocrine disorders			
Precocious puberty			
subjects affected / exposed	1 / 20 (5.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences (all)	1	1	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	3 / 20 (15.00%)	5 / 42 (11.90%)	6 / 83 (7.23%)
occurrences (all)	6	5	7
Deformity thorax			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Bone pain			

subjects affected / exposed	1 / 20 (5.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences (all)	1	2	0
Back pain			
subjects affected / exposed	3 / 20 (15.00%)	11 / 42 (26.19%)	15 / 83 (18.07%)
occurrences (all)	3	14	16
Foot deformity			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	3 / 83 (3.61%)
occurrences (all)	0	0	4
Knee deformity			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	1	0	0
Joint range of motion decreased			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	2 / 83 (2.41%)
occurrences (all)	0	1	2
Joint laxity			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	1	0	0
Joint contracture			
subjects affected / exposed	8 / 20 (40.00%)	11 / 42 (26.19%)	21 / 83 (25.30%)
occurrences (all)	13	16	38
Hip deformity			
subjects affected / exposed	2 / 20 (10.00%)	1 / 42 (2.38%)	2 / 83 (2.41%)
occurrences (all)	2	1	3
Kyphoscoliosis			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	3 / 83 (3.61%)
occurrences (all)	0	1	6
Kyphosis			
subjects affected / exposed	1 / 20 (5.00%)	2 / 42 (4.76%)	3 / 83 (3.61%)
occurrences (all)	1	2	3
Muscle atrophy			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	1 / 20 (5.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences (all)	1	1	0
Muscle contracture			

subjects affected / exposed	6 / 20 (30.00%)	17 / 42 (40.48%)	37 / 83 (44.58%)
occurrences (all)	19	38	67
Musculoskeletal chest pain			
subjects affected / exposed	1 / 20 (5.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences (all)	1	2	0
Limb asymmetry			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	1 / 83 (1.20%)
occurrences (all)	0	1	1
Pain in extremity			
subjects affected / exposed	1 / 20 (5.00%)	4 / 42 (9.52%)	6 / 83 (7.23%)
occurrences (all)	1	6	6
Pathological fracture			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	1	0	0
Scoliosis			
subjects affected / exposed	6 / 20 (30.00%)	22 / 42 (52.38%)	33 / 83 (39.76%)
occurrences (all)	7	32	48
Spinal deformity			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	1	0	0
Neck pain			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	1 / 83 (1.20%)
occurrences (all)	0	1	1
Neuromuscular scoliosis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	2	0	1
Osteopenia			
subjects affected / exposed	2 / 20 (10.00%)	1 / 42 (2.38%)	3 / 83 (3.61%)
occurrences (all)	2	1	3
Osteoporosis			
subjects affected / exposed	2 / 20 (10.00%)	2 / 42 (4.76%)	0 / 83 (0.00%)
occurrences (all)	2	2	0
Tendinous contracture			



subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 42 (2.38%) 1	2 / 83 (2.41%) 2
Infections and infestations			
Abdominal abscess			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Bronchiolitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Adenovirus infection			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	2 / 83 (2.41%)
occurrences (all)	0	1	2
Bacterial disease carrier			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	2
Bacterial infection			
subjects affected / exposed	1 / 20 (5.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences (all)	1	1	0
Acute sinusitis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	1	0	1
Coronavirus infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Covid-19			
subjects affected / exposed	4 / 20 (20.00%)	8 / 42 (19.05%)	16 / 83 (19.28%)
occurrences (all)	4	8	19
Coxsackie viral infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	4 / 83 (4.82%)
occurrences (all)	0	1	4
Bronchitis			
subjects affected / exposed	2 / 20 (10.00%)	7 / 42 (16.67%)	5 / 83 (6.02%)
occurrences (all)	4	9	5

Cellulitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Clostridium difficile infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Croup infectious			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	3 / 83 (3.61%)
occurrences (all)	0	1	3
Ear infection			
subjects affected / exposed	3 / 20 (15.00%)	5 / 42 (11.90%)	14 / 83 (16.87%)
occurrences (all)	3	6	19
Ear infection fungal			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Enterovirus infection			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	2 / 83 (2.41%)
occurrences (all)	0	1	2
Gastroenteritis viral			
subjects affected / exposed	7 / 20 (35.00%)	5 / 42 (11.90%)	3 / 83 (3.61%)
occurrences (all)	7	5	7
Fungal skin infection			
subjects affected / exposed	1 / 20 (5.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences (all)	3	1	0
Gastritis viral			
subjects affected / exposed	2 / 20 (10.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences (all)	2	1	0
Gastroenteritis			
subjects affected / exposed	3 / 20 (15.00%)	4 / 42 (9.52%)	11 / 83 (13.25%)
occurrences (all)	3	10	15
Eye infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0

Gastrointestinal viral infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 42 (2.38%) 1	1 / 83 (1.20%) 1
Hand-foot-and-mouth disease subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 42 (2.38%) 1	3 / 83 (3.61%) 3
Hordeolum subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 42 (2.38%) 1	2 / 83 (2.41%) 3
Impetigo subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 42 (2.38%) 1	1 / 83 (1.20%) 2
Influenza subjects affected / exposed occurrences (all)	4 / 20 (20.00%) 4	6 / 42 (14.29%) 11	16 / 83 (19.28%) 20
Klebsiella infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Lower respiratory tract infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	3 / 83 (3.61%) 4
Lower respiratory tract infection viral subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Metapneumovirus infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Otitis externa subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	3 / 83 (3.61%) 3
Oral fungal infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Otitis media subjects affected / exposed occurrences (all)	4 / 20 (20.00%) 4	5 / 42 (11.90%) 10	6 / 83 (7.23%) 8

Otitis media acute			
subjects affected / exposed	0 / 20 (0.00%)	2 / 42 (4.76%)	2 / 83 (2.41%)
occurrences (all)	0	2	2
Moraxella infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Mycoplasma infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	4 / 20 (20.00%)	13 / 42 (30.95%)	27 / 83 (32.53%)
occurrences (all)	7	37	72
Oral candidiasis			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	0 / 83 (0.00%)
occurrences (all)	0	1	0
Pneumonia			
subjects affected / exposed	1 / 20 (5.00%)	6 / 42 (14.29%)	11 / 83 (13.25%)
occurrences (all)	1	6	21
Pharyngitis streptococcal			
subjects affected / exposed	3 / 20 (15.00%)	4 / 42 (9.52%)	8 / 83 (9.64%)
occurrences (all)	4	6	16
Pseudomonas infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Parainfluenzae virus infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	1 / 20 (5.00%)	4 / 42 (9.52%)	3 / 83 (3.61%)
occurrences (all)	1	5	3
Pneumonia bacterial			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1
Postoperative wound infection			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	1 / 83 (1.20%)
occurrences (all)	0	2	1

Respiratory syncytial virus infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	2 / 42 (4.76%) 2	1 / 83 (1.20%) 1
Pneumonia aspiration subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	3 / 42 (7.14%) 9	8 / 83 (9.64%) 10
Respiratory tract infection viral subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 3	1 / 42 (2.38%) 1	2 / 83 (2.41%) 2
Rhinitis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	3 / 42 (7.14%) 4	8 / 83 (9.64%) 16
Rhinovirus infection subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	3 / 42 (7.14%) 3	3 / 83 (3.61%) 4
Serratia infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Sinusitis subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2	3 / 42 (7.14%) 3	6 / 83 (7.23%) 13
Staphylococcal infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Stenotrophomonas infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Respiratory tract infection bacterial subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Stoma site infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0

Suspected covid-19 subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Tonsillitis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	3 / 42 (7.14%) 3	6 / 83 (7.23%) 6
Tooth abscess subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Stoma site cellulitis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	8 / 20 (40.00%) 14	21 / 42 (50.00%) 56	33 / 83 (39.76%) 63
Upper respiratory tract infection bacterial subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 3	4 / 42 (9.52%) 8	7 / 83 (8.43%) 12
Tracheitis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	0 / 83 (0.00%) 0
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	3 / 20 (15.00%) 4	4 / 42 (9.52%) 5	4 / 83 (4.82%) 5
Viral infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	2 / 42 (4.76%) 7	10 / 83 (12.05%) 11
Metabolism and nutrition disorders Feeding intolerance subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 42 (0.00%) 0	1 / 83 (1.20%) 1
Electrolyte imbalance			

subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1
Dehydration			
subjects affected / exposed	1 / 20 (5.00%)	4 / 42 (9.52%)	2 / 83 (2.41%)
occurrences (all)	1	4	2
Hypocalcaemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1
Hyponatraemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	1 / 83 (1.20%)
occurrences (all)	0	0	1
Hypokalaemia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	2 / 83 (2.41%)
occurrences (all)	0	1	3
Hypoglycaemia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	1 / 83 (1.20%)
occurrences (all)	0	2	1
Hypochloraemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Malnutrition			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	4 / 83 (4.82%)
occurrences (all)	0	0	4
Iron deficiency			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Hypovolaemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0
Metabolic acidosis			
subjects affected / exposed	0 / 20 (0.00%)	2 / 42 (4.76%)	2 / 83 (2.41%)
occurrences (all)	0	2	2
Obesity			
subjects affected / exposed	0 / 20 (0.00%)	2 / 42 (4.76%)	4 / 83 (4.82%)
occurrences (all)	0	2	4
Vitamin d deficiency			

subjects affected / exposed	0 / 20 (0.00%)	1 / 42 (2.38%)	1 / 83 (1.20%)
occurrences (all)	0	1	1
Weight gain poor			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	2 / 83 (2.41%)
occurrences (all)	0	0	2
Metabolic alkalosis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 42 (0.00%)	0 / 83 (0.00%)
occurrences (all)	0	0	0



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
01 November 2015	Allowed inclusion of participants who completed Study CS12 into Study CS11, and to provide clarifications and corrections to the original CS11 study protocol dated 12 May 2015.
30 January 2017	Transitioned the dosing regimen for the open-label maintenance dosing period for all index studies (ISIS 396443-CS3B [Groups 1A and 1B], ISIS 396443-CS4 [Groups 2A and 2B], ISIS 396443-CS12 [Group 3], and ISIS 396443-CS3A [Group 4]) to the MMDR schedule, during which maintenance doses of nusinersen were administered every 4 months.
29 October 2017	Allowed enrollment of participants from the newly added index study 232SM202 into this extension study. As a result of this change, the approximate number of participants had increased from 239 to 292 participants, the approximate number of study sites from 37 up to 45 sites, and the approximate number of countries from 14 up to 15 worldwide. Participants entering the extension study from the index study 232SM202 were enrolled into a new cohort, Group 5. Participants entered directly into the open-label period at MMDR Day 1.
18 November 2019	Changed the interval of clinical assessment visits after the Modified Maintenance Dosing Regimen (MMDR) Day 720 Visit from every 8 months to every 12 months.
23 March 2020	Changed the standard neurological examination to a focused neurological examination.
20 October 2021	Limited the number of participants who were receiving nusinersen concomitantly with other SMA therapies to 20% (n = 58) of the total population.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported